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ABSTRACT
Genome-Wide Association Analysis of Major Depressive Disorder and Its Related Phenotypes

by
Nagesh Aragam
Major Depressive Disorder (MDD) is a complex and chronic disease that ranks fourth as cause
of disability worldwide. Thirteen to 14 million adults in the U.S. are believed to have MDD and
an estimated 75% attempt suicide making MDD a major public health problem. Recently several
genome-wide association (GWA) studies of MDD have been reported; however, few GWA
studies focus on the analysis for MDD related phenotypes such as neuroticism and age at onset
of MDD. The purpose of this study is to determine risk factors for MDD, identify genome-wide
genetic variants affecting neuroticism and age at onset as quantitative traits, and detect gender
differences influencing neuroticism.

Bivariate and multiple logistic regression analyses were performed on 1,738 MDD cases and
1,618 non-MDD controls to determine phenotypic risk factors for MDD. Multiple linear
regression analyses in PLINK software were used for GWA analyses for neuroticism and age at
onset of MDD with 437,547 Single Nucleotide Polymorphisms (SNPs).

Gender (OR: 1.43; 95% CI: 1.24 – 1.64) and a family history (OR: 2.88; 95% CI: 2.48 – 3.35)
were significantly associated with an increased risk of MDD, which supports the findings of
prior studies. Through GWA analysis 34 SNPs were identified to be associated with neuroticism
(p < 10-4). The best SNP was rs4806846 within the TMPRSS9 gene (p = 7.79 x10-6).
Furthermore, 46 SNPs were found showing significant gene x gender interactions for
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neuroticism with p<10-4. The best SNP showing gene x gender interaction was rs2430132 (p =
5.37x10-6) in HMCN1 gene. In addition, GWA analysis showed that several SNPs within 4 genes
(GPR143, ASS1P4, MXRA5 and MAGEC1/2) were significantly associated with age at onset of
MDD (p < 5x10-7).

This study confirmed previous findings that MDD is associated with an increased prevalence in
women (about 43% more compared to men) and is highly heritable among first degree relatives.
Several novel genetic loci were identified to be associated with neuroticism and age at onset.
Gender differences were found in genetic influence of neuroticism. These findings offer the
potential for new insights into the pathogenesis of MDD.
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CHAPTER 1
INTRODUCTION
Major depressive disorder (MDD) is a chronic disease whose epidemiology has been studied
worldwide and clinically researched to understand its etiology, distribution, development, and
available treatments. MDD is characterized by its defining features of marked and persistent
depressive moods, appetite and weight changes, insomnia or hyperinsomnia, fatigue or loss of
energy, feelings of excessive guilt or worthlessness, poor concentration and/or indecisiveness,
recurrent thoughts of suicide or death, and psychomotor agitation or retardation (Boomsma et al.,
2008). MDD is distinct from normal sadness by its persistence for longer than 2 weeks, drug or
alcohol dependence, and somatic diseases (Sullivan et al., 2009). The definition of MDD
excludes other mental disorders such as, bipolar disorder, schizophrenia, and other
schizoaffective disorders. MDD has been found to be comorbid with nicotine dependence
(Cardenas et al., 2002), alcoholism (Miguel-Hidalgo et al., 2010), anxiety (Boomsma et al.,
2000), and other psychological problems. Those afflicted with MDD may suffer from the disease
throughout their lifetime. An estimated 75% of MDD afflicted people suffer from its chronic
status and have an increased risk of suicide.
MDD is a complex disease that affects the lives of both the patients and their families. It is a
major cause of disability worldwide, ranking 4th according to a recent survey of global burden of
disease; and estimated to become 2nd by 2030 (Mathers & Loncar, 2006). The prevalence
estimate for MDD in the United States National Comorbidity Survey - Replication (NCS-R)
sample is 6.7% for a 12-month period which is an estimated projection of 13.1 to 14.2 million
U.S. adults suffering from MDD during a 12-month period (Kessler et al., 2005). It has been
firmly established that the risk for MDD is partly genetic and family studies have found a
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significantly higher prevalence of MDD among biological relatives of MDD cases (Sullivan,
Neale, & Kendler, 2000). Despite the existence of a considerable amount of research on the
epidemiology and the biological correlates of MDD, the etiology of MDD remains unknown. An
important clue has been the familial tendency and the heritability of MDD which has led to a
number of genome-wide linkage studies with the identification of over 100 candidate genes
(Sullivan et al., 2008).

Significance
Genetic factors are important in the risk of MDD and heritability has been estimated at 35%40% (Kendler & Prescott 1999, Sullivan et al., 2000). MDD is frequently associated with
smoking (Husky et al., 2008), anxiety (Boomsma et al., 2000), marital problems (South &
Krueger 2008), and other psychological problems (Wade, Bulik, Neale, & Kendler, 2000).
Recent studies of MDD at the molecular and genetic levels provide increasing evidence linking
disease phenotypes with both genes and environment factors. Jabbi and coworkers have
reviewed data that supports a role of monoaminergic and other related genes in environmental
adaptation to conclude that convergent approaches may be useful in the examination of genetic
modulation of disease phenotypes (Jabbi, Korf, Ormel, Kema, & den Boer, 2008). The current
literature reveals that more sophisticated tools and methods are needed to understand the
etiology, prevalence, and genetic significance of MDD (The Psychiatric GWAS Consortium
Steering Committee, 2009).
Morbidity and mortality from MDD are significant public health problems as highlighted by
two Surgeon General Reports (U. S. Department of Health and Human Services, 1999; U. S.
Public Health Service, 1999). The Surgeon General’s Reports point out that suicide, a tragic
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consequence of MDD occurs in 10%-15% of patients previously hospitalized for depression
(Angst, Angst, & Stassen, 1999). This mortality is three times greater than that reported for the
general United States population (U. S. Public Health Service, 1999).
MDD is a highly heritable medical disorder and it is clear that the genetic etiology of MDD
is complex and multi-factorial. Studies have shown that gender is important to the course and
outcome of MDD. Silverstein (1999) described gender differences in the prevalence of clinical
depression and Lavretsky et al. (2004) reported on sex differences in brain structure in geriatric
depression. The gender-specific rate of MDD found in community samples agrees with the 1.7:1
prevalence of MDD reported for women vs. men (Marcus et al., 2005). Recently, Essau,
Lewinsohn, Seeley, and Sasagawa (2010) studied gender differences in the developmental course
of depression and found strong evidence for a female preponderance of MDD in adolescence and
adulthood. Immunoreactivity of cortical receptor proteins (NUDR and 5-HT1A) found in female
subjects with MDD by Szewczyk et al. (2009) was lower compared to their male cohorts.
Genetic and environmental factors may interact in their contribution to the risk of clinical
depression such as Major Depressive Disorder in adolescents and adults. As stated above, MDD
frequently coexists with smoking, anxiety, and other psychological problems. There has been
little effort to examine gender and genetic risks together. Genetic and gender interaction may
explain previously observed discrepancies between studies looking at candidate environmental
agents and genes for MDD. Without accounting for these interactions the true main effects of
either the gender factor or the gene will not be identified. One strategy for increasing the
statistical power to detect MDD genes is to divide the phenotype into genetically meaningful
subtypes (also called endophenotypes) and use a sufficiently large sample size of the population
under study to decrease heterogeneity.
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Another strategy was proposed by Risch and Merikangas (1996) in their analysis of the
statistical power of linkage and association studies. By having a large number of genome-wide
Single Nucleotide Polymorphisms (SNPs) a case-control association study may be conducted to
associate specific SNPs and genomic regions with complex disease traits. Back in 1996, the
human genome had not yet been sequenced, but the hypothesis of Risch and Merikangas laid the
foundation for the genome-wide association studies that became a reality after 2004 when the
functional human genome was fully sequenced.
Identification of specific genes and gene x gender interactions may point to identifying
specific population subgroups at increased risks for MDD. The findings have the potential to
help with understanding the genetic associations, predicting the risk, and developing treatments
for MDD. Increased understanding of how genetic factors and gender interact to alter the risks
for depression may allow us to provide new targets for therapy. Identifying genes that may
control the AAO of MDD would contribute to the understanding of MDD development and
progression and allow therapeutic interventions for delaying the onset of MDD for specific
families and population subgroups.

Research Purpose
The purpose of this research is to conduct Genome-Wide Association (GWA) analyses of
MDD affection, related phenotypes (e.g., neuroticism, anxiety), and age at onset (AAO) of
MDD.

Research Questions
This study addresses the following three research questions:
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1. Are gender and family history significantly associated with an increased risk of major
depressive disorder (MDD)?
2. Is neuroticism (a measurable, quantitative trait) a useful indicator of major depressive
disorder and are there any gene x gender interactions present?
3. Do the genetic components of age at onset help us to understand development of
major depressive disorder?

Research Hypotheses
Hypothesis 1
Being female, smoking, and family history of MDD are three of the strongest risk factors for
the development of MDD in the sample of European population from the Netherlands.
Rationale. With the availability of phenotypic information from a sizeable number of MDD
cases and non-MDD controls with 1,150 men and 2,206 women, carrying out statistically
meaningful linear and logistic regression analyses with a binary outcome as MDD affection for
multiple logistic regression analysis and a continuous quantitative outcome for multiple linear
regression analysis must be straightforward. In addition, with data available for a total of 10
predictors for depression, meaningful and strong asymptotic associations from the linear and
logistic regression would pare down the number of possible risk factors for MDD.
Hypothesis 2
Neuroticism as a continuous variable may increase statistical power of genome-wide
association analysis, and gender differences may exist in the genome-wide analysis of
neuroticism.
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Rationale. Neuroticism as an endophenotype for Major Depressive Disorder (MDD) is a
well-known, measurable, genetic, and environment-dependent mental condition. While
neuroticism has been recognized as one of the endophenotypes of MDD, few genome-wide
analyses of neuroticism as a quantitative trait have been reported to date. Neuroticism, as has
been conceptualized by Eysenck and Eysenck (1975), Hirschfield et al. (1983), and Pervin and
John (1990), is a personality trait that reflects emotional instability, vulnerability to stress, and
being anxiety prone. Neuroticism is considered as a moderate risk factor for major depression
disorder (MDD) and as a quantitative personality trait, neuroticism is moderately heritable
(Calboli et al., 2010). According to Bienvenu et al. (2001) neuroticism is the strongest predictor
of comorbidity of MDD.
Hypothesis 3
Age at onset as a quantitative trait may aid the identification of novel genetic variants for the
development of MDD.
Rationale. Although some genome-wide association studies of major depression disorder and
related comorbidity traits such as smoking, alcoholism, and neuroticism have been reported, few
studies have focused on the age at onset (AAO) of MDD. Luby (2009) asserts that empirical
evidence for clinical depression in children as young as age 3 has recently been validated. Other
studies have reported Traumatic Brain Injury (TBI) at an early age has led to higher rates of
major depression within 3 months of injury (Rao et al., 2010). Kovacs and Lopez-Duran (2010)
report that a compelling body of literature indicates that depressive symptoms in youngsters
predict subsequent MDD. Also, a Turkish study (Bilgi et al., 2010) suggests small frontal gray
matter volume leading to first-episode depression. However, few genome-wide studies in
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literature have reported on the analysis of age at onset of major depression.
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CHAPTER 2
LITERATURE REVIEW
Major depressive disorder (MDD) is a widespread and common mental condition that affects
persons of all cultures, races, genders, and ages (Millon, 2004). Both genetic and environmental
factors influence the occurrence of MDD. MDD has been diagnosed using several approaches
and instruments, and these are constantly undergoing revisions and refinements (Kessler et al.,
2009).
The Diagnostic Interview Schedule (DIS) was one of the first instruments used to
epidemiologically study MDD (epidemiology catchment area (ECA) study by Kessler et al.,
1994). Currently, a standard instrument for measuring MDD is the World Mental Health (WMH)
Survey Initiative Version of the World Health Organization’s (WHO) Composite International
Diagnostic Interview (CIDI) (Kessler & Ustun, 2000). The first nationally representative survey
in the U.S. was conducted from 1990 to 1992 using a modified version of CIDI and a survey
method (using face-to-face interviews) similar to ECA. This survey is known as the National
Comorbidity Survey (NCS). A revised version of this survey (NCS-R) based on International
Classification of Diseases, 10th Revision (ICD-10) and Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition (DSM-IV) was reported by Kessler et al. using data from faceto-face interviews by professional interviewers from the Institute for Social Research at the
University of Michigan, Ann Arbor, between February 2001 and April 2003 (Kessler et al.,
2005). The diagnostic criteria used by instruments like CIDI are based on the DSM-IV published
by the American Psychiatric Association (APA). DSM diagnostic criteria are actively
undergoing revisions (an updated DSM-V was recently announced by APA) (Regier, 2009) and
is expanding to include newer diagnostic elements for such conditions as autism. In their study,
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“Epidemiology of major depressive disorder: Results from the NCS-R”, Kessler et al. report that
the prevalence estimates for CIDI/DSM-IV MDD in the total NCS-R sample (N = 9282) are
16.2% (95% CI, 15.1 – 17.3) for lifetime and 6.6% (95% CI, 5.9 – 7.3) for the 12 months before
the interview (Kessler et al., 2003).
Further details of lifetime prevalence of Major Depressive Disorder and Age at Onset
distributions as determined by the Kessler et al. (2003) study are given in Appendix A1 for the
interested reader.

Major Depressive Disorder and Related Phenotypes
Kessler and Ustun (2000) classify mental disorders under five categories as follows –
1. Mood, which includes major depression, neuroticism, bipolar disorder, and mania.
2. Anxiety, which includes panic disorder, phobias like agoraphobia, generalized
anxiety disorder, posttraumatic stress disorder (PTSD), and obsessive-compulsive
disorder (OCD).
3. Substance abuse, which includes alcohol abuse and dependence and nicotine
addiction.
4. Childhood-related, which includes attention-deficit hyperactivity disorder (ADHD),
conduct disorder, separation anxiety disorder, and oppositional-defiant disorder.
5. Others, which include eating disorders, premenstrual disorder, intermittent explosive
disorder, pathological gambling, etc.
Specific details regarding the diagnosis of the above mentioned mental disorders including
screening for signs and symptoms, discussion of lifetime reviews, risk factors, treatment, etc. are
discussed further in Kessler and Ustun (2000). The complete WMH-CIDI includes a screening
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module, 40 modules focusing on diagnoses, functioning, treatment, risk factors, sociodemographic correlates, and methodological factors. In addition, elaborate CDROM-based
training materials are available to teach interviewers to administer the tests and to teach the
administrators how to ensure the quality of data collected. An overview of the WMH-CIDI
development is presented in Appendix A2.
As is consistent for other complex disease traits, MDD shows strong evidence of heritability;
however, identification of the causal genes for MDD has not yet been successful. Results from
genome-wide linkage scans for MDD and related quantifiable personality traits show a
relationship with “harm avoidance” and “neuroticism”. Regions on chromosomes 1, 4, 5, 7, 8,
11, 12, and 13 show significant linkage signals, but, these findings have not been replicated
among other populations (Boomsma et al., 2008). Neuroticism, Index of Depressive
Symptomatology, and Beck’s Anxiety Disorder Inventory have all been found to be quantitative
traits for MDD. Neuroticism is a personality trait that reflects emotional instability, vulnerability
to stress, and being anxiety prone (Eysenck & Eysenck, 1975; Hirschfield, Klerman, Clayton, &
Keller, 1983; Pervin & John, 1990). Neuroticism is moderately heritable and is considered to be
a moderate risk factor for MDD (Calboli et al. 2010) and is the strongest comorbid predictor of
MDD (Bienvenu et al., 2001). Fanous, Gardner, Prescott, Cancro, and Kendler (2002) have
examined the genetic and environmental sources of covariation between neuroticism and MDD
but were not able to identify a significant gender difference. Hettema et al. (2006) have sought to
identify additional etiologic factors that contribute to the comorbidity of neuroticism with MDD.
Their findings show substantial, if not complete, overlap between the genetic factors that
influence individual variation in neuroticism and those that increase liability across the
internalizing disorders.

25

Major Depressive Disorder Affection as a Binary Outcome
In this study, MDD is considered as a binary outcome (i.e., Affected or Not Affected) that
has related phenotypes (or risk factors) that are both categorical (e.g., married or single or
widowed; smoking or non-smoking) and continuous (e.g., neuroticism and age at onset).
Risk Factors of Major Depressive Disorder
The phenotypes, gender, marital status (living with a partner is considered as being married),
smoking status, alcohol use, and family history of depression are either binary or categorical and
require little further explanation. Age and Age at Onset are continuous variables taking values of
10-90 years depending on the specific population being used in a study.
The phenotypes determining the traits of neuroticism, anxiety severity, depression
symptomatology, and age at onset are further described as follows. Neuroticism is considered as
a personality trait associated with several mental disorders and is considered as a risk factor for
the development of MDD, anxiety disorders, and dementia (Calboli et al., 2010). A widely used
measure for neuroticism is the NEO personality inventory (Costa & McCrae, 1992) which
measures the following five dimensions of personality – Neuroticism, Extraversion, Openness,
Agreeableness, and Conscientiousness (also collectively known as NEO-Five Factor Inventory
or NEO-FFI). A score based on the subject’s response to a 5-point scale (‘strongly disagree’ to
‘strongly agree’) for each of the dimensions of personality in a 60-item questionnaire is totaled to
give a total score called the NEO-FFI total score (Guerrera et al., 2005). This continuous variable
is then used to determine along with other predictor variables (e.g., Inventory of Depressive
Symptomatology and Beck’s Anxiety Inventory scores) a binary predictor variable that is used as

26

the outcome - the MDD affliction status (i.e., affected / not affected) for use in logistic regression
analyses of MDD.
The inventory of depressive symptomatology (IDS) is a 30-item questionnaire designed to
assess (and often quantify the severity of) depressive symptoms. The assessment uses all the
criterion symptom domains designated by the American Psychiatry Association (APA)
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (APA, 1994). The time frame
for assessing the symptom severity is 7 days prior to the day of assessment. The Beck Anxiety
Inventory (BAI) is a 21-question multiple choice inventory created by Aaron T. Beck used for
measuring the severity of an individual’s anxiety level (Leyfer, Woodruff-Borden, KleinTasman, Fricke, & Mervis, 2006). Each question in the inventory has one answer out of four
(‘not at all’, ‘mildly’, ‘moderately’, and ‘severely’) with a point system coding each category.
For example, the answer ‘not at all’ scores 0-7 points, while the answer ‘severely’ scores 26-63.
Other MDD related phenotypes such as Age at Onset (AAO) of MDD, Anxiety Severity,
Depression Severity, and Neuroticism are defined below and their descriptive characteristics are
described later in chapter 3.


Age at onset is defined by Composite Interview Diagnostic Interview (CIDI) (Kessler
& Ustun, 2000) as the age when the first of the 2 years or longer a subject felt sad or
depressed.



Depression Severity is defined by the Inventory of Depressive Symptoms as a total
score computed by summing the 28 items symptom list in the CIDI interview.



Anxiety Severity is defined by the Beck Anxiety Inventory which is a total score
computed by summing the 21 items symptom list in the CIDI interview.
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Brief Survey of Major Depressive Disorder Phenotypic Studies
The psychiatric and psychopathologic literature is abundant with phenotypic studies of MDD
focusing on gender difference (e.g., Goodwin & Gotlib, 2004; Hakamata et al., 2009; Hyde,
Mezulis, and Abramson, 2008; Parker & Hadzi-Pavlovic, 2004; Silverstein, 1999), marital
problems and/or partner violence (e.g., Shorey et al., 2011; South & Krueger, 2008), smoking
status (e.g., Cardenas et al., 2002; Gulec et al., 2005), family history (Lazary, Gonda, Benko,
Gacser, & Bagdy, 2009), and alcohol use (e.g., Miguel-Hidalgo et al., 2010). Each of these MDD
phenotypes has been researched well, and the following subsections briefly summarize the
previous work.
The reported heritability of neuroticism is equal or greater than heritability estimates for
MDD (Calboli et al., 2010). The heritability of neuroticism has been estimated at 0.30 – 0.50
based on twin studies (Birley et al., 2006; Bouchard & Loehlin, 2001; Floderus-Myrhed,
Pederson and Rasmuson, 1980; Jang, Livesley & Vernon, 1996; Martin et al., 2000) along with
genetic covariance with depression and anxiety (Jardine, Martin, & Henderson, 1984; Fanous et
al., 2002; Hettema, Prescott, & Kendler, 2004; Hettema, Neale, Myers, Prescott, & Kendler,
2006; Huezo-Diaz, Tandon, & Aitchison, 2005; Kendler, Neale, Kessler, Heath, & Eaves, 1992,
1993). A link between genotype and personality has been tried to be established by several
researchers using NEO PI-R facets. For example, Persson et al. (2000) have shown an
association between a polymorphism in the tyrosine hydroxylase gene and personality traits, but,
Tochigi et al. (2006) report that they could not confirm the association with the tyrosine
hydroxylase gene. However, in a classic study by Lesch et al. (1996) a relationship between the
serotonin transporter gene regulatory region (5-HTTLPR) and neuroticism has been found.
Furthermore, it was found that individuals with a shorter allele version of the gene had higher
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neuroticism scores and was significant for both heterozygous and homozygous versions of the
allele. The authors further predict that approximately 10 to 15 genes in the 5-HTTLPR region
might be implicated in the moderation of neuroticism scores (Lesch et al., 1996).
Gender Difference and Major Depressive Disorder
The importance of gender on the course and outcome in MDD has been widely
acknowledged. For example, Silverstein (1999) described the gender difference in the prevalence
of clinical depression, while Lavretsky et al. (2004) reported sex differences in brain structure in
geriatric depression. The gender-specific rate of MDD is proportional to rates found in
community samples with a 1.7:1 prevalence of MDD in women vs. men (Marcus et al., 2005).
Recently Esau et al. (2010) studied the gender differences in the developmental course of
depression. Especially, gender-specific associations of NUDR and 5-HT1A receptor proteins with
MDD were reported by Szewczyk et al. (2009).
Hyde et al. (2008) in trying to find an integrated model of affective (emotional reactivity),
biological (genetic vulnerability, pubertal hormone, timing, and development) and cognitive
(cognitive style, objectified body consciousness, and rumination) have summarized the state-ofthe-art in gender differences for MDD. Accordingly, several factors can be attributed to the
higher prevalence of MDD in girls than boys and in women than men as follows –


Greater ruminative coping (Nolen-Hoeksema & Girgus, 1994)



Dependence on relationships or affiliative needs (Cyranowski, Frank, Young, &
Shear, 2000)



Ovarian and adrenal hormonal changes in puberty (Goodyer, Herbert, Tamplin, &
Altham, 2000)



Genetic factors (Kendler et al., 1993; Zubenko et al., 2002)
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Body dissatisfaction (Nolen-Hoeksema & Girgus, 1994)



Greater cognitive vulnerability (Hankin & Abramson, 2001)



Exposure to negative life events like rape and child sexual abuse (Kendler, Gardner,
& Prescott, 2002)



Gender intensification and adherence to traditional gender roles (Aube, Fichman,
Saltaris, & Koestner, 2000)



Interactions among the above listed factors (Hankin & Abramson, 2001).

While an in-depth summary of each of the above study is beyond the scope of this report,
suffice is it to say that the female gender has specific biological and cognitive factors that are
unique to the gender and thus the manifestation of higher prevalence of MDD in females does
not seem to be unnatural. In particular, the social factors like body image, traditional role playing
(this would especially be true in Asian and Mid-eastern cultures), and lack of access to equal
rights (e.g., to education) may breed gender differences right from the moment of birth for girls
and women.
According to Essau et al. (2010) the greatest increase in gender difference occurs between
the ages of 15 and 18 and the underlying mechanisms for this are not clear. It seems to generally
reflect the interplay of gender socialization, hormonal changes, and stressful life events
associated with adolescence (Cyranowski et al., 2000). Thus Essau and coworkers who studied
the developmental course of MDD in a project (Oregon Adolescent Depression Project) with 773
participants concluded that childhood depression may be a more serious risk factor for girls than
boys.
More interestingly however, Szewczyk et al. (2009) point to some basic biological reasoning
in terms of the gender-specific alterations in cortical NUDR protein receptor gene. Female
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subjects with MDD in their study had reduced protein expression of NUDR and 5-HT1A
receptors in the prefrontal cortex. Thus, they attribute biological factors for higher prevalence of
MDD in females.
Thus it seems that both social and biological factors play a big role in understanding the
gender differences and prevalence of MDD in girls and women. This area of understanding the
1.7:1 prevalence of MDD in women has become a prime target with researchers in psychology,
psychiatry, molecular biology, and epidemiology.
Smoking Status and Major Depressive Disorder
Husky et al. (2008) conducted an epidemiological study to determine whether smoking
behavior was associated with MDD, and further if the association was greater in women. They
used data from the National Epidemiologic Survey on Alcohol and Related Conditions
(NESARC). The details of data collection and the sample are published elsewhere (Grant et al.,
2003). Relationships between smoking status (categorized as daily, occasional, prior) and DSMIV MDD by gender were assessed in terms of odds ratios using logistic regressions. The results
showed that women with prior smoking were at significantly higher risk of current and past
MDD than men (OR: 1.53 vs 1.36; 1.72 vs 1.36). Similarly, the results for current occasional –
the ORs were 1.92 vs 1.39; 1.9 vs 1.3; and for daily smoking – the ORs were 2.52 vs 1.95; 1.84
vs 1.48.
MDD and nicotine dependence are highly comorbid (Cardenas et al., 2002). It seems that the
MDD patients may use nicotine to ameliorate their depressive symptoms. Cardenas et al.
hypothesized that a dysfunctional brain reward system (BRS) might link the use of nicotine and
MDD neurobiologically to enhance the dopaminergic activity. So they conducted a double-blind
case-control study with 34 subjects (18 nicotine-dependent cases and 16 nicotine-independent

31

controls) to assess their hypothesis. The results were mixed in the sense that the nicotine (or
smoking) did not modify the response to d-amphetamine in either cases or controls, but it
decreased the overall negative mood state during placebo sessions. The researchers concluded
that although the BRS may be dysfunctional in MDD cases, chronic nicotine use does not modify
response to d-amphetamine. In my personal opinion, the sample size (34) was too small to be
able to conclude anything definitively.
In another cross-sectional study of association between smoking and depressive symptoms in
Turkey the researchers found the smokers among medical students were 2.2 times more likely to
have depressive symptoms than nonsmokers (Gulec et al., 2003).
Family History and Major Depressive Disorder
As stated earlier, MDD has been shown to have a heritability of almost 40% (Kendler &
Prescott, 1999). MDD as an affective disorder has been shown to be both inherited and
influenced by environmental factors such as living in a household with diagnosed MDD cases
(Lazary et al., 2009). However, sufficient knowledge concerning inherited background and how
the environmental factors moderate the onset of MDD is still unknown. Lazary and coworkers
studied how affective temperaments (AT) and affective family history (AFH) relate to depressive
symptoms in a general population. They used 501 Hungarian adults to measure and analyze the
mediation of AT in AFH groups. Not surprisingly, a critical part of inherited factors of
depression is mediated by affective temperaments. The probability of having dominant
temperament was more than two-fold in the group with AFH than one without.
ATs are hypothesized to be associated with phenotypic expression of affective disorders
(Whittle, Allen, Lubman, & Yucel, 2006) and their relevance to endophenotype studies has also
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been proposed (Gonda et al., 2006). But much remains to be done in this area to fully understand
the role of family history in the development of MDD and other depressive disorders.
Marital Problems and Major Depressive Disorder
South and Krueger (2008) opine that marital distress may exert influence on MDD by acting
as a stressor. They conducted a study of marital quality on a range of mental disorders (including
symptoms for MDD) in 379 twin pairs concordant for marriage. A phenotypic factor analysis
was first conducted to confirm that one factor best accounted for the variance shared between
MDD and other mental disorders. Then they investigated the overlap between genetic and
environmental influences on both marital quality and internalizing spectrum to find genetic
influences common to both phenotypes. Their conclusion was that those with a genetic
predisposition to internalizing syndromes may be more likely to express the predisposition in
context of a dissatisfying marriage.
Alcohol Use and Major Depressive Disorder
Miguel-Hidalgo et al. (2010) studied MDD and alcohol use in a more clinical context by
measuring the levels of excitatory amino acid transporters (EAATs) 1 and 2 in a case-control
experiment. Their results show that the EAAT2 immunoreactivity was significantly lower in
MDD cases than in controls as were the levels of EAAT1. Their clinical conclusion is that there
are differential changes in the expression of glial glutamatergic markers in depression and
alcoholism suggesting a depletion of certain aspects of glutamatergic processing in MDD cases.
Thus alcohol may influence MDD through complex processes in the prefrontal cortex that are
still unknown.
Interestingly enough, Nurnberger, Jr. et al. (2001) have found evidence using genome-wide
sibling-pair linkage analysis of comorbid alcoholism and MDD to conclude that certain genes
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may influence both predisposition to alcoholism as well as detrimental diseases like MDD. They
evidence a specific locus (or a genetic marker) on chromosome 1 that is responsible to this dual
vulnerability. This was a part of the collaborative study on the genetics of alcoholism from the
National Institute on Alcohol Abuse and Alcoholism and the data from this study were used to
test three phenotypes – comorbid alcoholism and depression, alcoholism or depression, and just
depression. It is also worth noting in the Nurnberger et al. study that a majority of subjects with
alcoholism problem in this data set were men and a majority of subjects with depression were
women. Thus, the study may have limitations with confounding effects along with interactions
between alcoholism and depression.
However, some epidemiological studies have also shown researchers the positive effects of
coping with MDD by using moderate alcohol consumption and the comorbidity of alcohol use
and MDD needs to be researched further to elucidate our understanding of alcoholism as a
predictor or risk factor of MDD.

Genetic Studies of Major Depressive Disorder and Related Phenotypes
Before the human genome was completely sequenced, genetic studies took the form of
family, twin, linkage, and association studies that dealt with how genetic information was
transmitted and inherited down through generations of affected patients of a disease to be
studied. Most often these diseases were non-Mendelian, complex, and chronic diseases like
Alzheimer’s, Parkinson’s, Major Depression, etc. The main thrust of these genetic studies was to
figure out how diseases are carried through genetic markers and how studying the genes of
immediate family members like twins, parents and children, and siblings might show patterns of
disease linked genes in specific genetic regions and how they get inherited via strong linkages on
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specific chromosomes. An excellent overview of these genetic studies is given in “Statistical
Genetics: Gene Mapping through Linkage and Association” by Neale, Ferreira, Medland, and
Posthuma (2009).
A brief review of genetic linkage and association studies of MDD and its phenotypes in the
literature is given below. For detailed discussion of any one method or one phenotype linkage
mapping across an individual family genome or inheritance patterns, the reader is referred to a
plethora of information available in the PubMed. We discuss a sample of representative family
studies, linkage studies, and association studies of MDD below.
Genetic Family studies of Major Depressive Disorder
To explore the continuities and discontinuities between MDD in children and adolescents and
MDD in adults, Klein, Lewinsohn, Seeley, and Rhode (2001) use family studies. In their study of
268 adolescents with a history of MDD, 110 adolescents with non-MDD disorders, and 291
adolescents with no history of mental disorders they found evidence of familial aggregation of
adolescent MDD. They also found considerable specificity in the pattern of familial
transmission.
They used hazard ratios (HRs) to measure the increased risk for family members of a MDD
afflicted patient and they found the following –


Elevated rates of MDD (HR: 1.77, 95% CI: 1.46 – 2.31)



Dysthymia (HR: 1.79, 95% CI: 1.11 – 2.87)



Alcohol abuse or dependence (HR: 1.29, 95% CI: 1.05 – 1.53)

This pattern of MDD transmission within families was also found for other mental disorders
like anxiety disorder, substance abuse, and antisocial behavior.
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According to the literature available on family studies and MDD, it seems that the heritability
poses almost a three-fold increase in risk (2.84) according Sullivan et al. (2000). However, it has
also been established that families share MDD along with other phenotypic manifestations such
as mood disorders (esp. bipolar), schizophrenia, and neuroticism. Golster-Dubner, GaliliWeistubb, and Segman (2010) criticized that a family-based association study of MDD may not
pick up large genetic effects for MDD. They make the point that MDD coexists in families with
other mental disorders like schizophrenia, bipolar disorder, and neuroticism, and thus any family
association of MDD may be only small and overlapping with other mental disorder effects. In
addition, two separate studies (Liu et al., 2009; Serretti et al., 2003) trying to link specific genes
(BDNF) and specific enzymes (e.g. tyrosine hydroxylase) that are known to have a role in
depression within a family failed to produce family-based associations. This might be due to the
small genetic effects mentioned earlier for MDD and the fact that the specific etiology of family
inheritance of MDD is still largely unknown.
Genetic Linkage Studies of Major Depressive Disorder
Genetic risk factors are well established for MDD and a twin study has indicated >70%
heritability in twins (McGuffin, Katz, Watkins, & Rutherford, 1996). Genome-Wide linkage
analysis was carried out by McGuffin et al. (2005) in a sample of 497 sib pairs concordant for
recurrent MDD. The study found linkages on chromosomes 1, 12, and 13 at 1p36, 12q23.3 –
q24.11, and 13q31.1 – q31.3 respectively, while implicating genes MTHFR and DAO. The 12q
region has already been implicated with other mental disorders like schizophrenia and bipolar
disorders and the 13q region has been linked to panic disorders. A previous report of a locus on
15q also showed genome-wide significance for recurrent depression and the current 12q findings
are also genome-wide significant.
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In 2003 Zubenko and his team of coworkers used the genome-wide linkage studies to report
genetic loci influencing the recurrent early-onset MDD (RE-MDD) (Zubenko et al., 2003). This
study found 392 highly informative polymorphisms with an average spacing of 9 cM in the
region of the CREB1 gene. Nineteen chromosomal regions contained linkage peaks and 10
reached an adjusted p-value of < 0.001. Five loci showed evidence of interaction with the
CREB1 locus, and the authors of the report concluded that genes whose products participate in
cellular signaling pathways that converge on CREB region harbor alleles that affect the
development of MDD.
Holmans et al. (2004) conducted a study of genome-wide significant linkage to RE-MDD on
the region of chromosome 15q using 297 informative families containing 415 independent
affected sibling pairs and 685 informative relative pairs. All affected cases were diagnosed
before the person turned 31, and the affected relatives had a mean AAO of 41 years. GenomeWide significant linkage was observed on chromosome 15q25.3-26.2 with an empirical genomewide p-value of 0.023. These findings indicate chromosome 15 as a strong candidate for further
studies of MDD susceptibility.
In a replication study Camp et al. (2005) used Utah pedigrees to identify loci that influenced
RE-MDD and anxiety disorders. They used 87 large extended Utah pedigrees to investigate three
phenotypes: RE-MDD and anxiety, RE-MDD or anxiety, and RE-MDD and anxiety. They
replicated the earlier loci on 12q, 7p, and 18q and identified further interesting regions on 4q and
15q. Their study suggests some overlapping genetic etiologies between MDD and anxiety
disorder.
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Candidate Gene Association Studies of Major Depressive Disorder
Several candidate genes such as the CFH gene, the FTO gene, the TCF7L2 gene, and the
IL23R gene have been shown to be associated with MDD (e.g., Boomsma et al., 2008).
Increased risk for MDD has also been established in a study by Traks et al. (2008) which relates
the MDD risk to IL20 and IL24 genes and suggest that cytokines may contribute to the
pathogenesis of MDD. A recent study by Rietschel et al. (2008) has implicated the G72 gene
with MDD and neuroticism in large population-based groups in Germany. More recently, Shyn
and Hamilton (2010) have presented an intensive review.
In a classic paper by Cordell and Clayton (2005), the authors discuss the rationale behind
genetic association studies. Traditional epidemiologic studies of environmental risk factors and
genetic studies have a lot of similarities, but there are issues specific to the studies of genetic risk
factors (e.g. use of specific family-based designs), population history, and underlying genetic
mechanisms. Genetic association differs from genetic linkage in that the alleles of interest will be
the same across the whole study population while linkage allows different alleles to be associated
with the disease trait in different families.
Genetic associations can be direct or indirect, confounded or with interactions, consider
direct relationship between genotype and phenotype, or it could be indirect relationship with the
consideration of linkage disequilibrium. A brief literature review of the genetic associations of
two of the MDD traits we have proposed to study (i.e., neuroticism and age at onset) is given
below.
Calboli et al. (2010) have found that neuroticism is a moderately heritable MDD trait and a
risk factor for developing MDD. They performed a genome-wide association analysis of 2,235
participants drawn from a large population-based study of neuroticism using 430,000 autosomal
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SNPs together with 1.3 million imputed SNPs from the HapMap CEU samples (Gibbs et al.,
2003). They found that the gene NKAIN2 showed suggestive association (p < 10-6) with
neuroticism as a main effect and the gene GPC6 showing evidence of interaction (p ≈ 10-7) with
age. They found support for one previously associated association with the gene PDE4D but
failed to replicate other recent finds. They concluded that common SNP variation does not
strongly influence neuroticism.
Brummett, Boyle, Kuhn, Siegler, and Williams (2008) examined prolactin responses to a
tryptophan challenge as they relate to the Neuroticism, Extraversion, Openness, Agreeableness,
and Conscientiousness (NEO Five Factor Inventory or NEO-FFI used to measure neuroticism
quantitatively; described more fully in 2.1) using 67 volunteers. Their findings indicate that the
gender moderated the association between neuroticism and prolactin level (p < 0.03) and higher
levels of neuroticism were associated with decreased levels of prolactin responses in females;
males responded exactly opposite, i.e., higher levels of prolactin produced higher levels of
neuroticism.
Lake, Eaves, Maes, Heath, and Martin (2000) examined the hypothesis that environmental
transmission is a significant factor in individual differences for neuroticism among 45,850
members of extended twin kinships from Australia (N=20,945) and the U.S. (N=24,905). They
found no such evidence of environmental transmission influencing neuroticism levels in
replicated samples from two different continents, concluding that a simple genetic structure
underlies familial resemblance for the neuroticism trait.
In a study of gene x environment interactions in mental disorders Tsuang, Bar, Stone, and
Faraone (2004) state that association studies provide potentially useful approach to the detection
of gene-environment interactions in mental disorders. They point to depression-like behaviors in
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rats and various nonhuman protocols when they are exposed to environmental stress such as
maternal separation, neglect, and social deprivation. However, the behavioral responses differ
depending on the individual genetics and the interaction effects of the environment on the genes.
Unlike neuroticism, the age at onset of MDD has not been explored under the umbrella of
genetic association studies, especially in cases of early childhood depression in children as young
as age 3 (Luby, 2009). However, the literature points to several linkage studies of recurrent,
early-onset major depression (Camp et al., 2005; Holmans et al., 2004; Zubenko et al., 2003).
These were discussed earlier under genetic linkage studies. Other genetic association studies of
MDD involving specific genes such as 5-HTTLPR and IL-6 are discussed next.
Myung et al. (2010) studied the serotonin transporter gene polymorphisms and chronic
depression recurrence in Korean subjects using 252 patients with MDD. The patients were
genotyped for s/l polymorphisms in 5-HTT promoter and s/l variation in the second intron of the
5-HTT gene (5-HTT VNTR intron 2). Chronicity was associated with 5-HTTLPR where the l/l
allele showed higher rate of chronicity than s/l or s/s varieties (OR: 4.45; 95% CI: 1.59 – 12.46;
p = 0.005). Thus 5-HTTLPR was implicated in the association with MDD, while the 5-HTT
VNTR intron2 was not.
Uddin et al. (2010) studied epigenetic differences between patients with lifetime MDD and
those without. They used a community-based sample in a Detroit neighborhood taken from a
sample of participants in the Detroit neighborhood Health Study (DNHS). Their sample
contained 33 persons with lifetime MDD and 67 persons without lifetime MDD. Bioinformatic
analyses were performed on the genes uniquely methylated and unmethylated in each group and
inflammatory biomarkers Interleukin 6 (IL-6) and C-reactive protein (CRP) were measured to
investigate the possible significance of the methylation profile. Their conclusion was that
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examining epigenetic mechanisms in concert with other dynamic markers of physiologic
functioning could improve our understanding of neurobiology of depression.
Lesch (2004) comprehensively studied MDD and the gene x environment interactions for
MDD in a paper describing how starting from family studies and linkage studies the research has
moved on to the genetic association studies of MDD. Investigation of subtle alterations in gene
expression, correlations between genotype and brain activity and of environmental variables
interacting with genetic variants have advanced research into the genetics of depression. He adds
that gene-phenotype correlations have been substantiated by functional neuroimaging and the
notion of gene networks that control brain development is increasingly recognized. However,
given the etiologic and psychobiologic complexities of mental disorders, identification of
specific genetic factors is extremely difficult and gene hunting continues.
MDD like other complex genetic diseases is heterogeneous in origin and is polygenic where
different susceptibility genes may be operating in different families. Thus the gene x
environment interactions need to be fully evaluated before understanding the etiology of MDD
and there is a need to investigate the molecular basis of MDD. This is discussed in the next
subsection briefly.
Molecular Basis of Major Depressive Disorder
Jabbi et al. (2008) point out that there is growing evidence linking disease phenotypes with
genes on one hand and the genesis of stress related disorders like MDD as a result of exposure to
environmental pathogens on the other. They conclude that advocating the use of convergent
approaches in examining the genetic modulation of disease phenotypes might be useful. Taking
the example of MDD and a few well-known MDD associated genes (e.g., 5-HTT, MAOA, and
COMT) the researchers explored the gene x gene interactions to find out how certain genetic
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markers may result to endophenotypes like HPA axis dysfunction leading to susceptibility for
some of the co-occurring neuropsychiatric disorders like MDD and neuroticism. They further
point to such results as HPA-axis involvement in the maintenance of homeostasis during stress
and a speculation of interaction between COMT and MAOA on peripheral endocrine
responsivity to stress may be related to a combined influence of these genes affecting the CRH
functioning. Thus understanding genetic associations at the molecular functioning level are
needed to further understand MDD and the modulation of complex behavioral adaptations
relevant for a disease phenotype. Further discussion of this topic is beyond the scope of this
report.

Genome-Wide Association Studies of Major Depressive Disorder
Large-scale studies are needed with multiple phenotypes, DNA, and ideally, biological
material that enables gene expression and other genomic and proteomic analyses. Genome-Wide
analysis study is one such large-scale undertaking with data collected over several years in order
to identify potential genes and genomic regions that are significant in patients diagnosed with
cases of MDD.
The conventional genome-wide association study (GWAS) approach is a hypothesis-free,
systematic search of tagging Single Nucleotide Polymorphisms (SNPs) across the human
genome to identify novel gene associations with common diseases and has emerged as a
powerful tool to identify disease-related genes for many common human disorders and other
phenotypes (Guessous, Gwinn, & Khoury, 2009; McCarthy et al. 2008; Wellcome Trust Case
Control Consortium 2007). Recently, several GWAS of MDD have been reported. For example,
Sullivan et al. (2009) reported the possible role for the presynaptic protein piccolo (gene PCLO);
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Shyn et al. (2009) found strong associations for genes ATP6V1B2, SP4, and GRM7 from a
meta-analysis; Garriock et al. (2010) found three SNPs within genes UBE3C, BMP7, and RORA
associated with MDD with p-values less than 1 x 10-5; and Shi et al. (2010) found SNPs within
the gene SP4. Also, shared genetic risks for MDD and bipolar disorder have been reported
(McMahon et al., 2010).
One of the first Genome-Wide Association (GWA) studies that examined gender differences
for MDD is now published online (Aragam, Wang, & Pan 2011). That study identified 40 malespecific and 56 female-specific MDD associated Single Nucleotide Polymorphisms (SNPs) with
P-values less than 10-4. In addition, 38 SNPs showing gene x gender interactions influencing
MDD (P < 10-4) were also found. The implicated genes in this study were LGSN, PCLO, FIGN,
and OR4B1.
A brief summary of Genomics and GWAS literature is provided in Appendix B for interested
readers.

Genome-Wide Association Studies of Neuroticism
In earlier GWA studies, van den Oord et al. (2009) have reported finding potential
association between the MAMDC1 gene and neuroticism, while Shifman et al. (2008) have
found suggestive association between the PDE4D gene and neuroticism in one sample and
replicated in another. However, replication in some other samples by Shifman et al. was not
possible. Terraciano et al. (2010) found potential association signals for all five neuroticism
scales, but the effect sizes were small and most associations failed to replicate in other samples.
Several researchers have also reported an association of Neuroticism and Alzheimer’s disease in
literature (Wang et al., 2009; Wilson et al., 2003).
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The differences in the quantitative trait scores for neuroticism in men and women have
been found to moderate the prevalence of MDD in females. Recently some studies of
neuroticism have been reported to identify gender differences in MDD severity as a function of
neuroticism total score (Eaves, Heath, Neale, Hewitt, & Martin, 1998; Fanous et al., 2002; Lake
et al., 2000; Liu et al., 2006) with the males showing consistently less severity than females
(Jardine et al., 1984; Jorm, 1987). Other population and gender studies on neuroticism in the
literature include, a twin study of the relationship between internalizing disorders and
neuroticism (Hettema et al., 2006), association of serotonergic function with neuroticism being
moderated by the gender (Brummett et al., 2008), neuroticism and dementia (Wang et al., 2009),
and prospectively assessed neuroticism association with anorexia nervosa among Swedish twins
(Bulik et al., 2006).

Summary
Literature about MDD as a psychiatric trait, or a disease phenotype, is well-known and has
been studied for a number of years. MDD is heritable, runs in families, and is found to be
comorbid with smoking and is more prevalent in women than in men. An elaborate international
instrument (WMH-CIDI) has been developed to study MDD epidemiologically and is in wide
use. MDD is a chronic disease by its own accord and should not be confused with other mental
disorders like bipolar disorder and schizophrenia. Furthermore, it is conceptualized as a binary
trait in this study although some experts argue otherwise.
Of late MDD is being studied as a complex genetic disease, and researchers are looking to
conduct genome-wide studies to understand and elucidate the genetic variants of this chronic
disease. Although strong correlations exist between neuroticism and MDD, few studies have
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looked at neuroticism as an endophenotype of MDD. Linkage and family studies have been
conducted widely in the past to unearth several genetic variants of MDD, but the implicated
genes have only been attributed to have small effects. Lately genome-wide studies have begun
with the availability of large amounts of genotype information and SNP data from selected
samples of MDD patients.
Genome-Wide association analysis is gaining ground as an attractive hypothesis-free
approach to study complex genetic diseases such as MDD. Although neuroticism and family
risks (i.e., being a first degree relative of someone who has been diagnosed with MDD) are
known predictors, few genome-wide studies using neuroticism and age at onset have been found
in the literature. In this proposed research study, both neuroticism and age at onset via inheriting
specific genes are studied to explore genome-wide association of MDD in a specific subset of
human population representative of the people with a European origin.
Determining the use of endophenotypes of MDD (e.g. neuroticism) as quantitative traits to
find the genetic variants of MDD and to find out how the analysis of age at onset of MDD as a
quantitative trait may help to understand the prevalence and severity of MDD lays the foundation
for this research work. A major goal of our study is that the study results will provide a genetic
basis for the elucidation of MDD and its phenotypes for future studies that examine other
populations.
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CHAPTER 3
MATERIALS AND METHODS
The overall goal of this research study is to understand and investigate the epidemiology and
underlying genetic basis for the onset, prevalence, and the chronic suffering (e.g., 12-month
disease burden, being disposed to such comorbidity as neuroticism) of those with major
depressive disorder (MDD). The following sections describe details of data sets and study
participants used for this research. A detailed study plan is also presented.

Datasets
The two data sets used in this research are briefly described below #1 GAIN Sample
This dataset is a combination of samples from the Netherlands Study of Depression and
Anxiety (NESDA) and the Netherlands Twin Registry (NTR). These data are available from the
public database of National Center for Biotechnology Information (NCBI), known as dbGaP.
Briefly, the data were collected from two longitudinal studies between 1991-2004 that used
clinical interviews, demographic questions, and biobanking home visits. Data collection for the
NESDA study was from 1996–2004 and for the NTR was from 1991-2004. There are 3,741
records in the combined NESDA and NTR data of which 1,991 records show a diagnosis of
MDD.
In 2006 a consortium of researchers from the University of North Carolina at Chapel Hill
(UNC-CH), Virje University in Amsterdam, and the Universities in Groningen and Leiden were
selected to genotype the combined NESDA and NTR samples in order to conduct a GWAS of
major depression. This study of MDD by the consortium of researchers came to be known as one
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of the six Genetic Association Information Network (GAIN) studies. The GAIN initiative is a
part of a public-private partnership of the Foundation for the National Institutes of Health Inc.
The funding for this initiative came from three pharmaceutical companies – Pfizer, Affymetrix,
and Abbott Laboratories. Not all 1991 NESDA cases were selected for the GAIN study and a
few of the non-MDD controls were added from the NESDA sample. Thus the combined NESDA
and NTR sample consists of 1,738 MDD cases and 1,773 controls with 1,213 males and 2,298
females.
Genotyping data using the Perlegen 600K SNP chips (total 437,547 filtered SNPs) are
available for 1,738 cases and 1,773 controls in the GAIN database. GWA genotyping for the
selected candidates (see Chapter 3 for details) was done by Perlegen Sciences and the Stage 1
results became available in 2007 via the National Center for Biotechnology Information (NCBI).
The complete database of candidates’ phenotype and genotype information is known as dbGaP
and it has the following web portal (http://www.ncbi.nlm.nih.gov). Access to this public
database requires preapproved applications for research in MDD with the restriction that use of
the genotype and phenotype data is limited to psychiatric health and related somatic conditions.

#2 OZALC Sample
The data for the OZALC study were obtained from telephone diagnostic interviews of two
general population volunteer cohorts consisting of Australian twins and their spouses, – a total of
11,000 families. The data used come from the publicly available data from the Genome wide
Association Study of Alcohol Use and Alcohol Use Disorder in Australian Twin-Families
(OZALC GWAS) – Study Accession: phs000181.v1.p1. The details about these subjects are
described elsewhere (Grant et al., 2009, Nelson et al., 2004). Genotyping data using the Illumina
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Human CNV370v1 (total of 343,955 SNPs) are available for 4,119 individuals in this data set.
After merging with pedigree and phenotype of Anti-Social Personality Disorder (ASPD), we
removed one from each of 44 Monozygotic (MZ) twins and 72 outliers based on the data
description. Consequently, 103 cases of ASPD were left. This database is used for replication
study only and for finding common genetic variants in both Neuroticism and ASPD. This data
set is used in the study of gene x gender interaction of neuroticism.

Overview of Sample Selection, Data Collection, and Data Characteristics
Sample Selection
The defining features of MDD used for this study are those used for NESDA study and are
marked by persistent depressive moods associated with physical and cognitive signs and
symptoms (e.g., insomnia, anhedonia, appetite and weight changes, psychomotor agitation or
retardation, etc.) as described in Boomsma et al. (2008). The combined dataset also contain
severity indexes for mental disorders such as neuroticism and generalized anxiety disorder for
MDD cases.
Major Depressive Disorder Cases - Inclusions and Exclusions
The inclusion criteria for the MDD cases were:


WMH-CIDI diagnosis of MDD



Age between 18-65 years



Knowledge of Dutch language



North-European ancestry.

The exclusion criteria for the MDD cases were:
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People with primary diagnoses of psychosis, bipolar disorder, obsessive compulsion
disorder, severe addiction disorder



Insufficient knowledge of the Dutch language

Major Depressive Disorder Controls - Inclusions and Exclusions
The inclusion criteria for MDD controls were:


Never scoring high (> 0.65) on a general factor score for anxious depression



Never reported any history of MDD



Age between 18-65



Knowledge of Dutch language



North-European ancestry

The exclusion criteria for controls arose when there were multiple eligible controls in a
family. In that case, gender and age were matched with cases first and then the control that
completed the highest number of questions in the questionnaire was selected.
The selected cases and controls in the GAIN database were then genotyped by Perlegen
Sciences (Mountain View, CA) that was blinded as to the case or control status and the
corresponding SNP data were stored in the database of Genotypes and Phenotypes (dbGaP) as a
part of the GAIN initiative.
Data Collection
The NESDA cases were selected from households in 90 Dutch municipalities and had been
diagnosed with lifetime MDD or anxiety disorder during one of the CIDI interviews in 1996,
1997, or 1999. The total catchment area for NESDA had a population of 1,175,000 people and
selection was done using stratified random sampling to select potential study candidates and
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7,076 people responded. The sample also included a subgroup of 18-25 year olds that
participated in for the Adolescent at Risk for Anxiety and Depression.
The collaborative NESDA study involved four academic and two nonacademic centers.
NESDA was a longitudinal cohort study (1996 – 2004) that followed 2,850 persons, aged 18-65
years, and had five assessments, one at the baseline and after 1, 2, 4, and 8 years of follow-up.
The clinical diagnosis of MDD was based on a detailed survey. The criterion for a case selection
was the diagnosis of a depressive or anxiety disorder during a standardized intake assessment.
The process of recruitment consisted of three phases –
1. A preliminary screening questionnaire filled out at the GP’s office where the subject
consulted for depressive symptoms.
2. Those who screened positive were phone interviewed with the short form of the CIDI.
3. Those with current diagnosed MDD status were asked to participate in NESDA and
were further invited for a baseline assessment that included the full WMH-CIDI
interview.
The final inclusion criterion was a diagnosis of DSM-IV MDD, an age between 18 and 65
years and self-reported European ancestry (Boomsma et al., 2008).
The controls data from the NTR were collected longitudinally by mail surveys every 2-3
years since 1991. There are about 22,000 participants from 5,546 families who were all assessed
for depressive symptoms, anxiety, neuroticism, and other personality disorders. The controls
never scored high on a general factor score (mean = 0.0 and SD = 0.7; a score of > 0.65
constitutes depressive disorder) to qualify for anxious depression. The factor score was a
combined measure of neuroticism, depressive symptoms, and anxiety assessed via longitudinal
questionnaires. These control subjects never reported a history of MDD in any survey or the
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blood sampling visits. The controls were similar with cases in demographics (i.e., of Dutch
origin), gender distribution (40% men and 60% women), and age (18-65). But they did not have
a lifetime diagnosis of MDD or anxiety disorder as assessed by the WMH-CIDI. There were also
a few (167) healthy controls selected from NESDA study in this sample. Further details of
selection objectives, recruitment, and methods of NESDA have been described elsewhere
(Boomsma et al., 2008; Kessler, et al. 2003; Penninx, et al., 2008).
Data Characteristics
Baseline characteristics of cases and controls are summarized in Tables 1 and 2 given on the
website (www.ncbi.nlm.nih.gov/dbgap) on October 9, 2007. Accordingly, the ages of
participants (both cases and controls) were not significantly different, but the number of women
in cases was higher than in controls. More controls were married or living with a partner (20%
more) than cases and there were almost double the number of cases who smoked (42% vs 20%)
compared to controls. Alcohol use was higher in controls than in cases (80% vs. 66%) and the
NEO neuroticism score had a higher mean in cases than in controls (39.3 vs. 28.2). More
complete details of how the data were collected, sampled, and the establishment of the Genetic
Association Information Network (GAIN) are described by Boomsma (Boomsma et al., 2008).

Table 1
Characteristics of GAIN MDD Cases
Characteristic

Predictor Type

MDD Cases; N = 1821

Age (years)

Continuous

42.1 ± 12.7

Female (% Yes)

Categorical

69.7

With Partner / Married (% Yes)

Categorical

68.5

Smoking (current in % Yes)

Categorical

42.1

Alcohol use (last year in % Yes)

Categorical

66.3

NEOa neuroticism score (0 – 60)

Continuous

39.3 ± 8.0
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Table 1 (Continued)

Family history of MDD (% Yes)

Categorical

85.4

Depression; Age at Onset (years)

Continuous

27.5 ± 12.3

IDSb depression (0 – 69)

Continuous

25.8 ± 13.5

BAIc anxiety (0 -62)

Continuous

14.3 ± 10.6

For continuous traits, the mean score and SD are listed.
a

NEO = Neuroticism, Extrovertness, Openness.

b

c

IDS = Index of Depressive Symptomatology.

BAI = Beck’s Anxiety Inventory.

Table 2
Characteristics of GAIN MDD Controls
Characteristic

Predictor Type

MDD Controls; N = 1822

Age (years)

Continuous

45.1 ± 14.1

Female (% Yes)

Categorical

61.8

With Partner / Married (% Yes)

Categorical

87.0

Smoking (current in % Yes)

Categorical

20.4

Alcohol use (last year in % Yes)

Categorical

80.0

NEOa neuroticism score (0 - 60)

Continuous

28.2 ± 5.5

ABVb neuroticism score (11 -124)

Continuous

36.7 ± 16.0

ABV somatic complaints (12 – 46)

Continuous

15.9 ± 3.8

STAIc trait anxiety (20 – 79)

Continuous

30.1 ± 5.6

YASRd anxious depression (0 – 21)

Continuous

3.22 ± 2.7

Beck depression (0 – 23)

Continuous

1.11 ± 1.4

For continuous traits, the mean score and SD are listed.
a

NEO = Neuroticism, Extrovertness, Openness.

b

ABV = Amsterdam Biographic Survey.

c

STAI = Spielberger Trait Anxiety Inventory.

d

YASR = Young Adult Self Report.
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Formation of dbGaP
From the NESDA participants the cases for the GAIN MDD study and genotyping were
selected from September 2004 through February 2007. Although an initial 1,821 cases and 1,822
controls were available for analyses, final selection in the GAIN sample excluded certain
subjects (because of genotyping and sample problems) and included some others (e.g., parents of
some controls) to form trios (the subject and his/her parents). After the above adjustments a total
of 1,860 cases and 1,857 controls were included in the GAIN database.
Figure 1 below illustrates the make-up of the GAIN database of genotypes and phenotypes
(dbGaP). The phenotype data for NESDA consisted of responses from the WMH-CIDI forms
(described in Appendix A2) and represented MDD, depressive symptoms, and other
psychopathology indicators. In addition, the CIDI interview also provided information on age at
onset, number of episodes of MDD, and specific symptoms of depression along with quantitative
scores for NEO-FFI, IDS and BAI.
The biobank samples from NESDA and NTR participants were collected and stored at the
time of their baseline visit for CIDI interviews (for NESDA participants) and a separate blood or
urine collection project (for NTR participants). All necessary protocols were followed for
collection, storage, and genotyping of the biosamples. The dbGaP holds both phenotype and
genotype information for cases and controls. The individual researcher or the team of researchers
who gets access to the data in dbGaP might be required to reformat the data tables to suit the
needs of a particular study.
For example, a data item in a specific column of a table in the database might not be useful
for a specific study and may have to be deleted; or, one may want to categorize a continuous data
item (e.g., age of 18-65 may be categorized into 18-30, 31-60, 61+), etc. In case of genotypes
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data one may have to filter the data for conformity with Hardy-Weinberg proportion and
Minimum Allele Frequency (usually > 1%) and so one might eliminate certain SNPs and
individual data row.
Formation of dbGaP Database

Cases’
Phenotypes

Controls’
Phenotypes

dbGaP
NESDA

NTR

Cases + Controls
Genotypes
Cases’
Biosamples

Controls’
Biosamples

Perlegen Genotyping
Services

Quality
Control
Biosamples

Figure 1. Formation of dbGaP

In addition, one may want to eliminate outliers in the data and so might need to use other
software tools to run the data required first before making it ready for the required analyses. This
type of preliminary processing for needed quality control of the data is the responsibility of the
researcher who is given access to the dbGaP data.
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Study Designs for Data Analyses
Using the two data sets described above, three study designs are developed below for
addressing the three research questions we identified earlier in chapter 1. These are given below:
Study Design for Research Goal #1: Risk Factors for Major Depressive Disorder
Only the primary data set #1 GAIN dbGaP described earlier was used to address this research
goal.
Study population. Data from 3,356 individual records sampled from the NESDA/NTR
phenotypes dataset and stored in GAIN dbGaP was used to conduct descriptive and regression
analyses.
Study Variables. Four continuous and five categorical predictor variables are used in order to
determine the various quantitative relationships. These are shown in Table 3.
Table 3
Study Variables Used for Research Goal #1
Outcome Variable

MDD Affection Status (Binary)

Predictor Variables

Age (continuous)
Gender (categorical)
Marital status (categorical)
Smoking Status (categorical)
Alcohol Use (categorical)
Family Risk (categorical)
Neuroticism (NEO) (continuous)
Index of Depressive Symptomatology (IDS)
(continuous)
Beck’s Anxiety Index (BAI) (continuous)

Neuroticism (Continuous)

Age (continuous)
Gender (categorical)
Marital status (categorical)
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Table 3 (Continued)

Smoking Status (categorical)
Alcohol Use (categorical)
Family Risk (categorical)
Index of Depressive Symptomatology (IDS)
(continuous)
Beck’s Anxiety Index (BAI) (continuous)
Age at Onset (Continuous)

Gender (categorical)
Marital status (categorical)
Smoking Status (categorical)
Alcohol Use (categorical)
Family Risk (categorical)
Index of Depressive Symptomatology (IDS)
(continuous)
Beck’s Anxiety Index (BAI) (continuous)
Neuroticism (NEO) (continuous)

The potential confounders are Age, Gender, Marital Status, Smoking Status, Alcohol Use,
and Family Risk. The potential effect modifiers are Gender, Smoking Status, and Family Risk.
Statistical Methods
Descriptive Analyses. SAS 9.2 and SPSS 17 were used for descriptive analyses. Univariate
analysis was conducted to obtain baseline information prior to conducting more advanced
bivariate and multiple variable analyses. The univariate analysis of MDD phenotypes such as
NEO, IDS, and BAI provide us an estimate of distributions of phenotypes in the study
population. Histograms and box plots were used to graphically show and compare the prevalence
of specific MDD phenotypes for men and women, married and unmarried, smokers and
nonsmokers, and so forth. We hope to replicate prior established facts such as a higher
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prevalence of MDD in females as opposed to males, comorbidity smoking and MDD, and
described familial risks for MDD such as an affected first-degree relative increasing the risk of
MDD in individuals. In addition, the statistical distributions of continuous and categorical
predictors are plotted using SPSS software.
Bivariate Analyses. Simple logistic regression methods were used to analyze the data in order
to evaluate the association of the covariates and MDD. Bivariate logistic regressions of the
primary outcome variable (MDD affection) were carried out for age, neuroticism score, gender,
marital status, smoking status, alcohol use, and family risk. The results were used to examine the
strength of the potential risk association of the different predictors for MDD and its related
phenotypes.
Multiple Variable Analyses. Multiple logistic regressions were used to measure the
relationship between the outcome variable MDD affection and the different predictors of interest.
Multiple logistic regressions use an odds ratio (OR) to assess the association and potential risk of
MDD affection for one predictor while adjusting for all other predictors or covariates. The
covariates that were used for multiple logistic regression of MDD affection are – age, gender,
marital status, smoking status, alcohol use, neuroticism score, and family risk. Multiple linear
regressions of continuous predictors like NEO, IDS, and BAI assess the relationship between the
continuous outcome variable (NEO, IDS, BAI) and a predictor like age, gender, marital status,
smoking status, etc. while adjusting for all other covariates.
The SAS procedures used for analyses are “proc reg”, “proc logistic”, and Generalized
Linear Model (“proc glm”). Odds ratios along with Wald confidence intervals for MDD with
predictor variables are computed using the multiple logistic regression procedure. The multiple
regression procedures used ‘backward’ selection of variables and included only those predictors
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that were significant at the level of 0.05 alpha values. In addition, interactions were tested for the
three leading predictor variables - gender, smoking status, and family risk. The “glm” procedure
is used with the predictors gender, marital status, smoking status, alcohol use, and family risk as class variables to discover potential confounding effects. After eliminating the confounding
effects of predictors using multiple variable regressions a reasonable relationship between the
primary outcome variable (MDD affection) and the predictor variables (MDD phenotypes) were
assessed.
Study Design for Research Goal #2: Genome-Wide Association Analysis of Neuroticism
Two data sets are used in this study – one primary (#1 GAIN dbGaP) and one secondary (#2
OZALC) for replication purposes. The data sets #1 and #2 were described earlier in the sections
on data sources and participants.
Study Population. For this Research Goal, 2,748 individuals (902 males and 1,846 females)
were analyzed. There were 437,547 SNPs available for the data. These managed data were the
result of the data quality control and stratification steps taken in the previous phase. Any
additional data management required before analyzing the continuous severity variables selected
using PLINK and/or other software was accomplished first. The second data set is used for
comparing the results of significant SNPs obtained in the association studies with the significant
SNPs obtained from a family-based association analysis of Australian twins for Anti-Social
Personality Disorder (Wang et al., 2011).
Study Variables. Both phenotypic and genotypic variables were used in this study. The
outcome variable Neuroticism (NEO) and the predictor Age were continuous variables and the
covariates Gender and Genotype were categorical. The genotypes of 902 males and 1,846
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females available from the study data set #1 were used for both neuroticism association and gene
x gender interaction studies.
Statistical Methods.
Quality Control. For the initial GWA analysis of MDD, HelixTree Software
(http://www.goldenhelix.com/SNP_Variation/HelixTree/index.html) was used to assess genotype
data for conformity with Hardy-Weinberg equilibrium (HWE). To deal with population
stratification, the principal-component analysis approach (Price et al., 2006) in HelixTree was
used to identify outlier individuals.
Linear Model. To test for association with a quantitative trait, linear regression was
performed by PLINK to obtain the regression coefficient and Wald test asymptotic p-value. In
addition to obtaining nominal P-values, empirical P-values are generated by 100,000 permutation
tests using Max (T) permutation procedure implemented in PLINK. In this procedure, the
corrected values for multiple testing (corrected empirical P-values) are calculated.
1. Gender-specific association study with separate male and female samples
(a) QT = b0 + b1*ADD + b2*Gender + b3*Age + e
where, QT is a quantitative trait (neuroticism), ADD is a dummy variable for coding the
possible genotypes AA, Aa, and aa with the additive model; Gender is the variable for coding
male or female sample data in the additive model; b0 is the intercept, b1, b2, b3 are the
corresponding regression coefficients, and e is the error term.
For neuroticism, we used (a) to perform association analysis for MDD case samples controlling
age.
2. Gene x gender interactions of neuroticism
(b) QT = b0 + b1*ADD + b2*Gender + b3*ADDxGender + b4*Age + e
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where, QT is the quantitative trait (Neuroticism) being analyzed, ADD is the dummy variable
for coding three genotypes AA, Aa, and aa with additive model, b0, b1, b2, b3, and b4 are the
corresponding intercept, individual regression coefficients, Age and Gender are the covariates
being used and e is the error term.
For neuroticism, we used (b) to test gene x gender interactions controlling age.
Statistical Significance. We used a conservative per test significance level of α=5x10-7
(Wellcome Trust Case Control Consortium, 2007). At the same time, we also had a less stringent
criterion of “suggestive association” with a cut-off of α=10-4.
Study Design for Research Goal #3: Genome-Wide Association Analysis of Age at Onset
Only the primary data set #1 GAIN dbGaP as described earlier was used for this analysis.
Study Population. Sixteen hundred three subjects (481 males and 1,122 females) were used
for this analysis. There were 437,547 SNPs available for the data. This managed data were the
result of the data quality control and stratification steps taken in the previous phase. Any
additional data management required before analyzing the continuous severity variables selected
using PLINK and/or other software were accomplished first.
Study Variables. Both phenotypic and genotypic variables were used in this study. The
outcome variable Age at Onset (AAO) was a continuous variable and the covariates Gender and
Genotype were categorical. The genotypes of 481 males and 1,122 females available from the
study data set #1 were used for AAO association with MDD.
Statistical Methods
Linear Model. Linear model analysis was performed for AAO using PLINK v1.07 (Purcell et
al., 2007). To test for association with AAO as a quantitative trait, linear regression was
performed by PLINK to obtain the regression coefficient and Wald test asymptotic p-value.
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(a) QT = b0 + b1*ADD + b2*Gender + e
where, QT is a quantitative trait (Age at Onset), ADD is a dummy variable for coding the
possible genotypes AA, Aa, and aa with the additive model; Gender was the variable for
coding male or female sample data in the additive model; b0 is the intercept, b1 and b2 are
the corresponding regression coefficients, and e is the error term.
For Age at Onset we used (a) to perform association analysis for MDD case samples
controlling gender.
Statistical significance. We used a conservative per test significance level of α=5x10-7
(Wellcome Trust Case Control Consortium, 2007). At the same time, we also had a less
stringent criterion of “suggestive association” with a cut-off of α=10-4.
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CHAPTER 4
RESULTS
The results from the three studies identified in the previous chapter are presented here. First,
some of the results from the descriptive analyses are illustrated as graphical plots showing some
of the significant distributions of MDD related phenotypes in the sample population selected for
univariate analyses. The histograms illustrated below in Figure 2 correspond to two of the three
major predictors of MDD we have found, namely, gender and marital status. Because smoking is
both a confounder and a possible effect modifier, and because we do not know whether the
smoking data are pre- or postdiagnosis of MDD, we cannot rely on any illustrative
interpretations of the raw distribution plots that involve any smoking data.

Comparison of Mean Neuroticism Total Score in
a Sample from the Netherlands Study of MDD

Figure 2. Comparison of Mean Neuroticism Scores
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The histograms show the pattern of mean frequencies in our NESDA-based sample and
should not be generalized for any other population. From Figure 2 we can surmise that the mean
score for NEO-FFI in unmarried females seems to be slightly higher (in value) than unmarried
males but certainly higher than both married males and females.
In Figure 3 we see that the age at onset is the earliest in unmarried males while not much
difference is seen in case of females. The finding that unmarried males are prone to early age at
onset of MDD will need to be further evaluated by future studies.
In Appendix C we show some other histograms generated during the descriptive analysis and
Gene x Gender interaction analysis of Neuroticism scores in our sample.

Comparison of Mean Age at Onset of MDD in a
Sample from the Netherlands Study of MDD

Figure 3. Comparison of Mean Age at Onset
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Risk Factors of Major Depressive Disorder
The results from the logistic regression of Affection_Status of MDD for each of the predictor
variables – Age, Gender, Marital Status, Smoking Status, Alcohol Use, Family Risk and NEO
Score are summarized in Table 4 below. They all show statistically significant relationships with
MDD. The OR estimates indicate that Age, Marital Status, and Alcohol Use show a reduction in
risk OR < 1); all others show increased risks (OR > 1). The bivariate analyses do not adjust for
potential confounding and further evaluations are required. Table 4 shows the following odds
ratios and confidence intervals for each of the predictors tested – Age (OR: 0.984, 95%CI: 0.980
– 0.989); Gender (OR: 1.428, 95% CI: 1.242 – 1.643); Marital Status (OR: 0.327, 95% CI: 0.275
– 0.389); Smoking Status (OR: 2.879, 95% CI: 2.476 – 3.347); Alcohol Use (OR: 0.498, 95%
CI: 0.426 – 0.583); Family Risk (OR: 3.451, 95% CI: 2.423 – 4.916); NEO Score (OR: 1.243,
95% CI: 1.223 – 1.264).
Table 4 shows the bivariate analyses for Family Risk and NEO Score with reduced sample
sizes. The sample sizes for these analyses are reduced because the phenotypes evaluated apply
only to cases and some of the data (esp. for family risk) are missing in the dataset #1. Further
discussion of these results is deferred until Chapter 5.
Table 4
Bivariate Logistic Regression of Major Depressive Disorder with Predictor Variables
Outcome Variable = Affection_Status (MDD)
Predictor
Variable

N

Model Fit

Parameter

(-2LL)

Estimate

Wald χ2

p-value

OR

Age

3,510

4,827.322

-0.0156

37.8419

< 0.0001

0.984

Gender

3,511

4,841.868

0.3564

24.9257

< 0.0001

1.428

Marital Status

3,457

4,620.548

-1.1183

158.9867

< 0.0001

0.327
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95% CI for
OR

(0.980 –
0.989)
(1.242 –
1.643)
(0.275 –
0.389)

Table 4 (Continued)

Smoking

3,488

4,636.111

1.0574

189.4331

< 0.0001

2.879

Alcohol Use

3,380

4,606.269

-0.6965

75.7377

< 0.0001

0.498

Family Risk

1,826

1,018.826

1.2387

47.0730

< 0.0001

3.451

NEO Score

2,748

2,529.105

0.2176

666.5801

<0.0001

1.243

Status

(2.476 –
3.347)
(0.426 –
0.583)
(2.423 –
4.916)
(1.223 –
1.264)

Multiple variable regressions with adjustment for confounding must be carried out before
specific predictors might be held responsible for possible associations with the outcome of
diagnosed MDD affection in a subject from the study sample. Multiple variable logistic
regressions were run with the binary outcome variable (i.e., Affection_Status) for MDD and the
requisite predictors identified earlier – Age, Gender, Marital Status, Smoking Status, Alcohol
Use, and Family Risk. The SAS regression tool eliminated the predictor ‘Age’ from
consideration because of statistical insignificance (P-value > 0.05) and other reasons. We used
age as a continuous variable and did not categorize the age into different categories that could
have shown significance in certain age groups (e.g. postadolescence age of 17-25). The analysis
was carried out starting with the predictor family risk first; other predictors were added one at a
time in the following order – NEO Score, Smoking Status, Alcohol Use, Marital Status, and
Gender. The results of logistic multiple variable regressions of Affection_Status (for MDD) with
individual predictor variables are shown in Table 5 below. Tables 6, 7, and 8 show results from
the interaction studies of the significant predictors.
Table 5 shows the following odds ratios and confidence intervals for each of the predictors
tested – Gender-female (OR: 1.282, 95% CI: 1.078 – 1.602); Marital Status (OR: 0.432, 95% CI:
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0.330 – 0.564); Smoking Status (OR: 3.079, 95% CI: 2.447 – 3.874); Alcohol Use (OR: 0.407,
95% CI: 0.318 – 0.521); Family Risk (OR: 3.112, 95% CI: 2.172 – 4.461); NEO Score (OR:
1.231, 95% CI: 1.210 – 1.253). The predictor Age is not at all significant (p = 0.7496) and was
eliminated in the analysis as a predictor by the SAS program. The corresponding results for Age
are shown as greyed out in Table 5.
Our analyses demonstrate that the major risk factors for MDD are Gender, Smoking Status,
Family Risk, and NEO Score. The odds ratios (ORs) for Gender (female), Smoking Status,
Family Risk, and NEO Score all show increased risks for MDD. The adjustment for confounding
does not remove the higher risk of MDD that was noted for female Gender, Smoking Status and
the Family Risk (i.e., a history of depression among the first degree relatives. The interaction
between Gender and Smoking Status, Gender and Family Risk, and Smoking Status and Family
Risk do not show any significance at a 5% (alpha = 0.05) significance level. Further discussion
of these results is given in Chapter 5.

Table 5
Multiple Logistic Regression of Major Depressive Disorder with Predictor Variables
Outcome Variable = Affection_Status (MDD);
N = 2730; -2LogL = 2330.167; Wald χ2 =696.0755; p < 0.0000000001
Predictor

Parameter

Variable

Estimate

Age

Wald χ2

p-value

OR

95% CI for OR

-0.0013

0.1021

0.7493

0.999

(0.991 – 1.006)

Gender

+1.2488

4.8161

0.0282

1.282

(1.078 – 1.602)

Marital Status

-0.8403

38.0185

0.0000000007

0.432

(0.330 – 0.564)

Smoking Status

+1.1245

23.7250

< 0.0000000001

3.079

(2.447 – 3.874)

Family Risk

+1.1354

38.2266

< 0.0000000001

3.112

(2.172 – 4.461)

Alcohol Use

-0.8980

50.9876

< 0.0000000001

0.407

(0.318 – 0.521)

NEO Score

+0.2082

565.9205

< 0.0000000001

1.231

(1.210 – 1.253)

66

Table 6
Multiple Logistic Regression of Major Depressive Disorder with Interaction Terms Gender*Smoking Status
Outcome Variable = Affection_Status (MDD);
N = 3488; Hosmer & Lemeshow Model Fit χ2 = 0.0000; p = 1.0000
Predictor

Parameter

Variable

Estimate

Gender
Smoking Status
Gender*Smoking
Status

Wald χ2

p-value

OR

95% CI for OR

0.3495

15.3997

< 0.0001

1.501

(1.298 – 1.735)

0.9678

59.1310

< 0.0001

2.966

(2.546 – 3.454)

0.1818

1.2941

0.2553

n/a

n/a

Table 7
Multiple Logistic Regression of Major Depressive Disorder with Interaction Terms Gender*Family Risk
Outcome Variable = Affection_Status (MDD);
N = 1826; Hosmer & Lemeshow Model Fit χ2 = 0.0000; p = 1.0000
Predictor

Parameter

Variable

Estimate

Gender
Family Risk
Gender*Family
Risk

Wald χ2

p-value

OR

95% CI for OR

0.3946

1.7784

0.1823

1.351

(0.933 – 1.958)

1.2680

20.8312

< 0.0001

3.293

(2.283 – 4.749)

-0.1117

0.0922

0.7614

n/a

n/a

Table 8
Multiple Logistic Regression of Major Depressive Disorder with Interaction Terms Smoking Status*Family Risk
Outcome Variable = Affection_Status (MDD);
N = 1825; Hosmer & Lemeshow Model Fit χ2 = 0.0000; p = 1.0000
Predictor

Parameter

Variable

Estimate

Smoking Status
Family Risk

Wald χ2

p-value

OR

95% CI for OR

1.2949

10.2781

0.0013

2.555

(1.686 – 3.872)

1.2646

38.1491

< 0.0001

2.970

(1.964 – 4.491)

-0.4264

0.8222

0.3645

n/a

n/a

Smoking
Status*Family
Risk
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Notice that the results for OR and 95% CI’s have been greyed out in tables 8, 9, and 10
above because the interaction terms are not significant at the p < 0.05 level and thus the
corresponding values of ORs and 95% CIs need to be recomputed.

Genome-Wide Association Analysis of Neuroticism
First we tested the association of neuroticism as a quantitative trait in PLINK to obtain the
Wald test asymptotic p-value. Thirty-four significant (p < 10-4) neuroticism (as a quantitative
trait) associated SNPs were detected in this analysis. Table 9 shows the top 20 neuroticism
associated SNPs along with any associated genes and/or flanking marker genes. Accordingly, the
best SNP associated with neuroticism (p < 10-5) was rs4806846 (p = 7.79x10-6) within
TMPRSS9 gene and the next best was rs220549 (p = 1.05x10-5) in GRIN2B gene. The SNP
rs1046329 (p = 1.37x10-5) in the gene SGCA is the third best. In addition, Table D-1 (Appendix
D) shows the complete list of asymptotic P-values for the 34 significant SNPs (p < 10-4) along
with the corresponding P-values in the separated male and female populations.
In Table 9 it is interesting to notice the widely differing p-values for males and females for
some significant (p < 10-4) SNPs. For example, for the SNP rs1046329 the female p-value is
2.88x10-5 whereas the same SNP is insignificant in males with p = 0.1835. Similarly, the SNP
rs4342432 is significant (p < 10-3) in females (p = 0.0001645) but not in males (p = 0.1475).
Table 9
Genome-Wide Association Study Results of Significant SNPs for Neuroticism in Major Depressive
Disorder
CHR

*

Reference
SNP

Positiona

Gene Name

Gene

P-value

Location

Total

b

P-value
Male

c

P-value
Femaled

19

rs4806846

2361484

TMPRSS9

19p13.3

7.79E-06

0.001109

0.002405

12

rs220549

13828587

GRIN2B

12p12

1.05E-05

0.05337

0.0002437
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Table 9 (Continued)
17

rs1046329

45603905

SGCA

17q21

1.37E-05

0.1835

2.88E-05

2

rs6757820

147996163

ACVR2A

2q22.3

1.51E-05

0.003489

0.002758

6

rs4510687

96219582

6q16.1

2.49E-05

0.1229

0.0001593

3

rs985280

64083893

3p14.1

2.61E-05

0.07875

0.0009192

6

rs4342432

96195874

2.96E-05

0.1475

0.0001645

16

rs9807002

26184920

3.05E-05

0.1409

0.000289

14

rs9323020

21228477

14q11.2

3.29E-05

0.06499

0.0001355

17

rs8068962

9254866

STX8

17p12

3.32E-05

0.05502

0.001416

2

rs2344734

152400075

NEB

2q22

3.61E-05

0.1872

0.0005467

2

rs12620464

101396078

4.09E-05

0.04817

0.0006929

8

rs1608361

123732642

4.13E-05

0.08719

0.004728

2

rs10930046

162846229

4.68E-05

0.06334

0.001034

5

rs6894463

3266546

4.81E-05

0.001539

0.003872

17

rs2301685

32452234

4.94E-05

0.1001

0.002558

20

rs6065392

39870080

5.02E-05

0.06333

0.001298

11

rs10835855

32165526

5.15E-05

0.06333

0.001298

8

rs16915079

51685259

8q11.22

5.54E-05

0.03473

0.006221

3

rs9834457

69604258

3p14.1

6.10E-05

0.02482

0.000309

(MANEA &
FUT9)
PSMD6

Near
EDDM3B

LOC1001315
52

ZHX3

8q24.13

20q12

Near
CYCSP22
Near
LOC642487

*

CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism

a

Physical position is based on NCBI genome build 36.3.

b

Wald test asymptotic P-value for the association of neuroticism with MDD in the total sample.

c

Wald test asymptotic P-value for the association of neuroticism with MDD in the male sample.

d

Wald test asymptotic P-value for the association of neuroticism with MDD in the female sample.

In addition, those significant SNPs (p < 10-1) that are significant for ASPD in the OZALC
study that share the same genomic regions as the significant (p < 10-1) neuroticism SNPs are
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shown in Table 10. Accordingly, 8 SNPs in the region of the significant gene markers (GRIN2B,
OR10G2, OR4E2, and RNASE1 on chromosomes 12 and 14) for association of neuroticism in
the NESDA sample were found with borderline associations for ASPD in the Australian sample
at a P-value of 0.09 or lower. Table D-4 shows the complete list of ASPD P-values for SNPs in
the region of implicated genes for neuroticism.
Table 10
Genome-Wide Association Study Results of Significant SNPs for ASPD in the Region of Implicated
Genes for Neuroticism*

CHR

*

Reference

Gene

SNP

Name

P-

P-

P-

P-

P-

P-

Neoneu

Neoneu

Neoneu

MDD-

MDD-

MDD-

Totala

Maleb

Femalec

Totald

Malee

Femalef

OZASPD
Sample
P-valueg

12

rs11055608

GRIN2B

0.9412

0.8302

0.5511

0.7588

0.3476

0.2884

0.06706

12

rs2216127

GRIN2B

0.08245

0.4308

0.07982

0.0391

0.1045

0.1781

0.04839

12

rs7974275

GRIN2B

0.865

0.9641

0.4977

0.4612

0.7569

0.2365

0.01938

14

rs10146821

OR10G2

0.08711

0.07005

0.7192

0.5681

0.3188

0.8758

0.04173

14

rs2874103

OR4E2

0.1635

0.8785

0.05961

0.2232

0.3295

0.3568

0.08020

14

rs970382

OR4E2

0.1826

0.8555

0.06383

0.2245

0.3046

0.3741

0.09011

14

rs718433

0.7877

0.643

0.5419

0.8413

0.7324

0.5755

0.05733

14

rs2141971

0.7169

0.2254

0.3192

0.3974

0.7782

0.1487

0.00448

Near
RNASE1
Near
RNASE1

CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism; MDD = Major Depressive

Disorder; ASPD = Anti-Social Personality Disorder.
a, b, c

Wald test asymptotic P-value for the association of neuroticism with MDD in the total, male, and

female sample.
d, e, f
g

Wald test asymptotic P-value for the association with MDD in the total, male, and female sample.

Wald test asymptotic P-value for the association with ASPD in the OZALC sample.
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Finally, Table 11 shows the top 20 significant (p < 10-4) gene x gender interaction SNPs for
neuroticism along with the corresponding Wald asymptotic P-values in the total, male-only and
female-only population in our sample discussed in Chapter 3. Table D-2 gives the complete list
of significant (p < 10-4) SNPs. Top three significant (p < 10-5) SNPs are rs243012 (p = 5.37x10-6)
in the gene HMCN1, rs17674783 (p = 6.92x10-6) in the gene SNTG1 and rs2612437 (p =
9.30x10-6) in the intergenic region between the genes MAP2K4 and MYOCD. These findings are
further elaborated in Chapter 5 in terms of any gene functionality and possibly other disease
associations available from the literature.
Table 11
Genome-Wide Association Study Results of Significant SNPs for Gene x Gender Interaction of
Neuroticism*
CHR

Reference
SNP

Gene Name

1

rs2430132

HMCN1

8

rs17674783

SNTG1

17

rs2612437

(MAP2K4 &
MYOCD)

12

rs11614157

4
8
4
20
3
15
20
14
2
15
15
8
6
5
8

rs244052
rs391798
rs13146994
rs6072394
rs9834626
rs870335
rs2326424
rs17111534
rs12692083
rs2415037
rs1532758
rs1023979
rs11970411
rs6595727
rs4412393

Gene
Location

P-assoc
Totala

P-assoc
Maleb

P-assoc
Femalec

P_GxE

1q25.3q31.1
8q11-q12

0.351

0.4283

0.6643

5.37E-06

0.8544

0.5047

0.999

6.92E-06

0.9471

0.526

0.5177

9.30E-06

0.0612

0.3835

0.2374

1.48E-05

0.2467

0.9248

0.4139

1.53E-05

0.9659
0.3128
0.2119
0.6774
0.9354
0.04644
0.3991
0.7659
0.8592
0.2269
0.2049
0.9345
0.1771
0.6117

0.483
0.2118
0.9787
0.454
0.4891
0.01311
0.9245
0.2809
0.5387
0.973
0.377
0.8628
0.02356
0.06589

0.8758
0.4046
0.3763
0.5157
0.411
0.2266
0.1688
0.09403
0.4015
0.07676
0.5902
0.8696
0.9237
0.3106

1.53E-05
1.66E-05
1.77E-05
1.78E-05
2.28E-05
2.69E-05
2.78E-05
2.83E-05
3.00E-05
3.50E-05
3.65E-05
3.66E-05
3.68E-05
3.75E-05

(PRP1R12A &
C12orf64)
ENPEP
SNTG1
ATP8A1

4q25
8q11-q12
4p14-p12

RPL10AP6
SMAD3
ADRA1D
LOC100288480
ISCA1P6
SMAD3
SMAD3

3p14.2
15q22.33
20p13
14q11.2
2q14.3
15q22.33
15q22.33

TNFA1P3

6q23
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Table 11 (Continued)
8
*

rs7832224

EFR3A

0.2561

8q24.22

0.8041

0.2023

4.21E-05

CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism; MDD = Major Depressive

Disorder;
a, b, c

Wald test asymptotic P-value for the association of neuroticism with MDD in the total, male, and

female sample.

Genome-Wide Association Analysis of Age at Onset of Major Depressive Disorder
The top 20 significant (p < 10-4) SNPs associated with age at onset in MDD cases are
tabulated below in Table 12. The highlighted portions in the table show SNPs that are significant
at the genome-wide level (i.e., p-value < 5x10-7). These are – rs734253 in the gene GPR143 (p =
2.54x10-12), rs6641545 in the gene ASS1P4 (p = 9.75x10-10), rs5983118 in the gene MXRA5 (p
= 5.67x10-8) and rs6654462 flanked by the genes MAGEC1 and MAGEC2 (p = 3.99x10-7). In
addition we have found three more highly significant (p < 10-5) SNPs at the 10-6 level which are
– rs32589 (p = 4.72x10-6), rs9294523 (p = 5.83x10-6), and rs10515638 (p = 9.77x10-6). The
complete list of associated (p < 10-4) SNPs for age at onset association is shown in Table D-5 in
Appendix D. In chapter 5, we elaborate more on the implicated genes for age at onset in terms of
any known functionality, association with other known diseases in both animal and human
models.
Table 12
Genome-Wide Association Study Results of Significant SNPs for Age at Onset of MDD*
CHR

Reference
SNP

Gene Name

Gene
Location

PMDDTotala

PMDDMaleb

PMDDFemalec

PNeuroticismd

23

rs734253

GPR143

Xp22.3

0.3747

N/A

0.8116

0.2357

23

rs6641545

ASS1P4

Xp22.33

0.7671

0.2733

0.2551

0.64

23

rs5983118

MXRA5

Xp22.33

0.398

N/A

0.1451

0.5025
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P-AAOe

2.54E12
9.75E10
5.67E08

Table 12 (Continued)

*

23

rs6654462

Flanked by
MAGEC1 and
MAGEC2

Xp26Xp27

0.3369

0.7451

0.1007

0.1432

5

rs32589

PPARGC1B

5q32

0.7074

0.0051

0.0168

0.5262

6

rs9294523

RPL5P19

6q15

0.5052

0.0952

0.0459

0.6942

5

rs10515638

PPARGC1B

5q32

0.8893

0.0133

0.1193

0.2302

5

rs26125

PPARGC1B

5q32

0.494

0.0068

0.0066

0.5332

23

rs5939057

ZCCHC16

Xq23

0.284

0.5247

0.1672

0.6689

5

rs17110375

PPARGC1B

5q32

0.62

0.0716

0.0686

0.0779

6

rs6570806

N/A

N/A

0.1601

0.0838

0.0129

0.8842

8

rs16938568

RDH10

8q21.11

0.6015

0.1612

0.9382

0.1362

12

rs11107320

LOC10013212
6

12q22

0.4294

0.2577

0.1283

0.1142

11

rs3016415

GRIK4

11q22.3

0.6102

0.0176

0.0251

0.8042

6

rs10947795

KCNK16

0.5245

0.0112

0.4695

0.2657

22

rs34074034

TTLL12

0.2529

0.0134

0.9774

0.4047

5

rs11738269

CANX

5q35

0.8539

0.0293

0.1304

0.2636

6

rs1876155

SIM1

6q16.3q21

0.1498

0.0672

0.5046

0.9709

15

rs11630901

RPAP1

15q15.1

0.1481

0.0037

0.9168

0.5768

8

rs17211245

RDH10

8q21.11

0.3178

0.1653

0.6283

0.0366

6p21.2p21.1
22q13.3
1

3.99E07
4.72E06
5.83E06
9.77E06
1.04E05
1.34E05
1.42E05
3.23E05
3.36E05
3.41E05
3.50E05
3.71E05
3.85E05
3.95E05
3.97E05
4.07E05
4.70E05

CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism; MDD = Major Depressive

Disorder;
a, b, c

Wald test asymptotic P-value for the association with MDD in the total, male, and female sample.

d

Wald test asymptotic P-value for the association of neuroticism with MDD in the total sample.

e

Wald test asymptotic P-value for the association of age at onset with MDD in the total sample.
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CHAPTER 5
DISCUSSION
Some of the expected phenotypic dependencies of MDD are discussed in the context of
our study findings and compared to the literature. The results of our genome-wide studies of
MDD in the Netherlands-based sample are discussed and the newly discovered significant SNPs
for MDD, neuroticism and age at onset of MDD will be considered. The study hypotheses
presented in Chapter 1 are considered according to our study results. A summary conclusion is
made and recommendations for future studies and directions for research into MDD using
GWAS are given.

Risk Factors of Major Depressive Disorder
Findings from the Univariate Analyses
The population used for univariate analyses contained 1,150 men and 2,206 women, 1,738
cases and 1,618 controls. Of these, 530 men and 1,208 women had MDD affection. There were
1,054 current smokers and 2,279 nonsmokers in the sample with a statistically significant risk for
smokers to be diagnosed with MDD and smoking as a risk factor for MDD has been well
reported in the literature (Husky et al., 2008).
A significant majority (73.77%) of the sample is identified as current users of alcohol, but
alcohol is not seen as a predictor for MDD from the multiple logistic regression analyses that
were performed later (details in subsequent sections) on the sample. Most of the subjects in the
study sample are either married or living with a partner while a minority reported a status of
being single or living without a partner. The association of having familial risk for MDD in the
study sample is significantly more (85.58%) as compared with those without any reported
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familial risks for MDD (14.42%). The presence of a first degree family member affected with a
depression disorder was identified using the Family Tree Assessment (Fyer & Weissman, 1999)
and was a part of the CIDI-based interview that was conducted on the subjects of the sample
during the data gathering process. The descriptive characteristics of cases and controls
summarized earlier in Chapter 3 in Tables 1 and 2 generally agree with the results of our
univariate analyses.
Findings from the Bivariate Analyses
Our study of regressing MDD as a binary trait using logistic regressions against selected
predictors seems to be one of the few in the literature as no other study has chosen the seven
predictors we have chosen, namely age, gender, marital status, smoking status, alcohol use,
family risk, and NEO score. Most other studies have concentrated on age, gender, marital status
as classic demographic variables along with such other socioeconomic variables as family
income, educational level, and living styles. Most studies using the dbGaP data seem to be
restricted to genotypic studies and not necessarily phenotypic in nature. Our study might be one
of the first to look at the epidemiology of MDD using the dbGaP data.
Our results support the findings of prior studies that female gender, smoking, and having an
affected first degree relative are all significant risk factors for being afflicted with MDD. The
association of family risk with an OR of 3.112 confirms the strong association of MDD within
families and that MDD is a genetically heritable disease. The association between gender and
MDD is shown by the 1.7:1 frequency among women as compared with men and an OR of 1.43
(95% CI: 1.24 – 1.64). This compares well to the literature where Kessler et al. (2003) reported
an OR of 1.4 (95% CI: 1.1 – 1.8) and Bromet et al. (2011) who recently reported a total OR of
1.8 (95% CI: 1.6 – 2.0) in high-income countries (e.g., Belgium, France, Germany, Japan,
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Netherlands, etc.) and low-income countries (e.g., Brazil, India, Columbia, Mexico, etc.) around
the world.
According to the study by Bromet et al. (2011), MDD is a significant public health concern
across all regions of the world and is strongly linked to social conditions. Three predictors – age,
gender, and marital status – are available as common study predictors for comparison of our
results. Comparing their gender results with our European (in particular, the Netherlands
population) sample the OR value of our sample (1.43) is much smaller than Bromet et al. study
sample which is reported to be 2.3 (95% CI: 1.5 – 3.5). They categorized age into four groups –
18-34, 35-49, 50-64, and 65+ and they also categorized marital status into five groups - never
married, separated, divorced, widowed, and currently married. But in our data set, age is a
continuous variable and marital status is binary and thus we cannot compare our results directly.
Our study must reconsider age as categorical and reformat our data to reflect their four age
groups and the regression rerun before we can compare the age as a risk factor. Their ORs for
marital status range from 2.6 to 1.9 with ‘65+’ category being the reference at 1.0. Similarly our
marital status OR is 3.05, but we need to categorize our marital status and the regression rerun
before attempting any comparisons. Their ORs range from 2.7 to 1.8 with currently married
category being the reference at 1.0.
MDD is also comorbid with smoking as shown by an OR of 2.88 (95% CI: 2.48 – 3.35)
which is consistent with other studies (Husky et al., 2008). Prevalence of depression among
cases who have a first degree relative being also diagnosed with some form of MDD is shown to
be the highest predictor (OR: 3.45 with 95% CI: 2.42 – 4.92) in our study. The family risk for
MDD shows up as a leading predictor for MDD in the study sample from the logistical
regression analyses. Several studies have linked chronic MDD to family history of depression
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(Camp et al., 2005; Gonda et al., 2006; Lazary et al., 2009). Lazary et al. (2009) use a different
phenotype called affective temperament that is measured via special instrument called TEMPS-A
(Kesebir et al., 2005). They concluded that a crucial part of inherited factors of depression is
mediated by affective temperament.
In addition, both alcohol usage and being married (or living with a partner) showed a
moderating effect with respective ORs of 0.498; 95% CI: (0.426-0.583) and 0.327; 95% CI:
(0.275 – 0.389) for being diagnosed with MDD. These results may point to the emotional and/or
calming (coping) effects of family bonds and alcohol. However, there are also many studies
about alcohol usage and MDD (see Chapter 2 for details) that shows an opposite effect.
Findings from the Multiple Variable Analyses
The results in Table 5 show that only age as a risk factor is removed upon multiple logistic
regression. The remaining risk factors marital status, smoking status, family risk, alcohol use and
NEO score continue to stay significant at p = 0.028 or much below that. The corresponding OR
values do not change much indicating minimal amounts of confounding among the risk factors.
As shown by Tables 6, 7, and 8 the analyses with interaction effects among the three major
predictors, gender, smoking, and family risk show little or no statistical significance. However,
the risk factor ‘smoking status’ has been classified as a binary variable and we do not have any
knowledge (data) of whether a person’s smoking status was pre- or postdiagnosis of being
afflicted with MDD. Thus the major risk factors for MDD from this study that could be
ascertained are gender, neuroticism, and family risk.
In terms of looking at our results, the odds ratio of 1.28 and 95% CI of (1.078 – 1.602)
gender is a significant risk factor with a modest chi-square value of 4.82 and a p-value of 0.028.
Smoking status has an OR of 3.07 (95% CI: 2.45 – 3.87) even after adjustment for other
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confounding variables and is a major risk factor of MDD. Looking back at the available literature
on smoking and MDD (Chapter 2.2), female gender and prior smoking together increase the risk
of MDD. From our results it seems that the smoking status of this particular female population
could have been “heavy or daily” as opposed to “occasional” or “prior”. This confirms other
studies on smoking and MDD that were cited earlier in Chapter 2 (Cardenas et al., 2002; Gulec
et al., 2003; Husky et al., 2008). Our results show an OR of 3.07 which is higher than the highest
found in the Husky et al. study where the smoking females had an OR value ranging from 1.36 to
2.52 corresponding to “prior user status” to “current daily user” status.
Both marital status (being married or living with a partner) and alcohol use seem to be
beneficial as indicated by their negative parameter values. However, from our earlier discussion
in Chapter 2 alcohol use has a more complex relationship with MDD. As has been reported in the
literature alcohol consumption when moderate could be beneficial to a person’s health, but
specific studies showing benefits for mental health are not found in the literature. Comparing the
OR of marital status from the bivariate analysis to the multiple variable analyses, we see a jump
in value from 0.327 to 0.432. While both values are well below 1.0, the confounding seems to be
beneficial and further analyses are needed to determine the particular risk factor that confounds
marital status as a risk factor for MDD. However, as South and Krueger (2008) point out, it is the
“marriage quality”, not just being married (which is all the information we have in our data)
might not reveal any suggestive relationship between MDD and marital status. South and
Krueger further point to environmental influences along with genetic influences that internalize
stressors, which in turn affects the psychopathology. Suffice is it to say that simple odds ratios
(albeit adjusted for confounding) may not be good indicators of possible risks that a marriage
may bring in terms of influencing a person’s (esp. a female’s) mental disorder. In summary, the
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genetic effects on the internalizing factor contribute to the development or worsening of MDD.
Further discussion of this complex subject is beyond the scope of this report.
As to be expected, the family history of MDD has a huge bearing on MDD shown by the OR
of 3.11 (95% CI: 2.17 – 4.46) which is slightly greater than what we have found for smoking.
Again, this association is more complex to be analyzed and results like adjusted odds ratios
might not reflect the underlying functional relationships. MDD is known to be heritable (up to
70% as some studies have shown) and both twin and family studies have contributed heavily and
will continue to do so in the future as genetic studies unearth more specific genetic regions and
SNPs where the predisposition to MDD may lie and how any pattern of inheritance could be
mapped. Multiple variable analyses may not throw any more light on this risk factor than the
simple bivariate analysis discussed earlier. However, our initial Hypothesis 1 (stated in Chapter
1) is true as has already been shown in the literature; i.e., being female, smoking, and family
history are all major risk factors for MDD.
The effect of NEO Score has been positive but the relationship between MDD and
neuroticism was further evaluated using GWAS methods by treating it as an endophenotype or a
quantitative trait of MDD. The results from our study are further discussed in the next section.

Genetic Association Analyses
We conducted genome-wide studies of two MDD related phenotypes, namely, neuroticism
and age at onset. Results from each of these studies are discussed separately below.
Genome-Wide Association Analysis of Neuroticism
A quick search in the OMIM and Entrez Gene databases for the implicated genes did reveal
some significant gene function or association with some mental disorders. The most significant
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association of neuroticism is with the gene TMPRSS9 containing the SNP rs4806846 (p =
7.79x10-6) at 19p13.3. This gene has been associated with the regulation of physiological and
pathological phenomena on the cell surface and has been implicated in congenital or childhoodonset form of deafness (Hayama et al., 2007). Functionally, Polyserase-1 transcripted from the
gene TMPRSS9 has alternative transcripts serase-1B and serase-2B (Okumura et al., 2006).
These have been found to be novel type II transmembrane serine proteases which may play a role
in regulating physiological and pathological phenomena on the cell surface. In other functional
studies, TMPRSS9 has been seen to possess a unique structure with three tandem serine protease
domains (serase-1, 2, and 3) (Cal et al., 2003).
The second best SNP rs220549 in the GRIN2B gene at 12p12 has been associated with
Schizophrenia (Doi et al., 2009), Bipolar Disorder (Fallin et al., 2005), Alzheimer’s disease
(Stein et al., 2010) and Obsessive Compulsive Disorder (OCD) (Arnold et al., 2009).
Functionally, GRIN2B is associated with Glutamate and N-Methyl D-Aspartic acid (NMDA)
receptors and have been found to participate as an excitotoxin for an operant behavior in
laboratory animals (Watkins et al., 2006). Both linkage and association studies of GRIN2B have
shown strong associations with Schizophrenia and Bipolar Disorder (Doi et al., 2009; Fallin et
al., 2005) in Ashkenazi Jewish population samples. A significant (p = 0.04) association of
GRIN2B has been identified by Arnold et al. (2009) with a decreased glutamatergic
concentration in the anterior cingulate cortex (ACC) that has been consistently implicated in
OCD. In addition, the NMDA protein encoded by the gene GRIN2B and is involved in learning
and memory along with excitotoxic cell death has age-dependent prevalence in the synapse and
is already a therapeutic target in Alzheimer’s disease (Stein et al., 2010).
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The third best neuroticism associated gene SGCA has been associated with limb girdle
muscular dystrophy, type 2D (LGMD2D) (Mendell et al., 2010) and embryonal
rhabdomyosarcoma in laboratory mice (Fernandez et al., 2010). In terms of association,
mutations in the SGCA gene may have caused LGMD2D in patients who were then subjected to
successful early phase gene therapy using adeno-associated virus (AAV) gene transfer under
control of a muscle specific promoter. Long-term, sustained gene expression of alphasarcoglycan may result in an effective treatment for LGMD2D (Mendell et al., 2010).
Functionally, the dystrophin-associated glycoprotein (DAG) complex is a group of muscle
proteins whose loss gives rise to muscular dystrophy. In laboratory mice lack of alphasarcoglycan (expressed by SGCA as a member of the DAG complex) results in a spontaneous
development of muscle-derived embryonal rhabdomyosarcoma (Fernandez et al., 2010).
Among other associated SNPs in Table 11, we found the SNP rs8068962 (p = 3.32x10-5) in
the gene STX8 at 17p12 associated with the Crohn’s disease (AceView, 2011). Two other
disease associated SNPs were – rs2344734 (p = 3.61x10-5) in the gene NEB associated with
Nemaline Myopathy (Wallgren-Petterson et al., 2007), and rs6065392 (p = 5.02x10-5) in the gene
ZHX3 associated with Primary Glomerula disease (Liu, Clement, Kanwar, Avila-Casado, &
Chugh, 2006). In fact, Wang et al. (2009) and Wilson et al. (2003) have suggested predictive
association of neuroticism with dementia and Alzheimer’s disease (AD) respectively. High
neuroticism has been associated with greater risk of dementia, while an active and socially
integrated lifestyle may modify the risk for dementia. Wang et al. (2009) conducted a
prospective study of 506 older people for 6 years to conclude that a combination of high
extraversion and low neuroticism is the personality trait required to maintain a low risk for
dementia (Wang et al., 2009). Wilson et al. (2003) used NEO-FFI neuroticism score to assess the
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disposition to experience psychological distress in a population of older Catholic nuns, priests,
and brothers participating in a Religious Orders Study of aging and Alzheimer’s disease. Their
findings showed the tendency to experience psychological distress predicted development of
incident AD and rate of cognitive decline (Wilson et al., 2003).
In addition, as shown by Table 12, several of these significant SNPs in the region showed up
as being significant for ASPD in an Australian sample (OZALC study) thus linking neuroticism
and antisocial behavior (Ducci et al., 2008; Schmidt et al., 2000; Wang et al., 2011). However,
further studies and replications are required before we can establish firm genome-wide
associations between neuroticism and anti-social behavior.
An analysis of the statistical power of our study using QUANTO software shows a power of
96% for the main effect using the neuroticism as a quantitative trait at a mean value of 39.3 ±
8.0, an allele frequency of 0.05, and a marginal R2 of 0.005. The main effect regression
coefficient was derived to be 1.8353. Looking back at our Hypothesis 2 (see Chapter 1), we
stated that neuroticism as a quantitative trait to conduct genome-wide association analysis may
increase the statistical power. A high statistical power of 96% that was achieved for this
particular sample population of Dutch origin in the Netherlands makes our hypothesis true.
However, many more replication studies are needed using other human populations before we
can confirm our hypothesis.
To our knowledge, this is the first GWA analysis of neuroticism as a quantitative trait of
MDD. Identification of a common genomic region between neuroticism in the NESDA
population and ASPD in the OZALC population may signal possible association between
neuroticism and ASPD that needs to be further investigated.
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Gene x Gender Interaction Analysis of Neuroticism
According to literature the HMCN1 gene has been associated with gene x environment
interaction in patients presenting atherosclerosis and two of the intervening environmental
factors have been gender and smoking (McGeachie et al., 2009). Another implication of the gene
HMCN1 is in age-related macular degeneration (AMD) that affects the renal functions
(Thompson et al., 2007). The authors report that the association of HMCN1 is not phenotypespecific and it appeared to influence the longitudinal rate of change of AMD while also
accounting for other risk factors like family history.
The gene SNTG1 encodes a protein specifically expressed in the brain and its transcript
variants have not been fully described, nor has their full-length nature been determined as of this
writing. The gene has also been implicated in personalized smoking cessation studies (Rose,
Behm, Drgon, Johnson, & Uhl, 2010) in terms of affecting the dosage of nicotine as an
environmental variable. The third most significant SNP rs2612437 (p = 9.3x10-6) is in the region
between genes MAP2K4 and MYOCD. The gene MAP2K4 encodes a dual specificity protein
kinase which is an activator of receptors to stressful signals from the environment, while the
gene MYOCD encodes a nuclear protein expressed in heart, aorta and other smooth muscle
containing tissues.
Thus so far, no specific or direct role of the implicated gene x gender interaction of
neuroticism genes have been connected to MDD, but they all seem to have some functional role
in the gene x environment interaction effects. Further studies and more functional analyses are
required to determine the specific roles of these genes. Detection of gene x gender interactions
provides a preliminary basis for the second part of Hypothesis 2 (stated in Chapter 1). However,
we again caution the need for replication studies using other samples before we could generalize
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our results as a determinant for the observed preponderance of higher prevalence of MDD in
females. In fact, the study of gene x gene and gene x environment interactions in GWAS is
extremely important before declaring any compelling associations.
In a perspective written by The Psychiatric GWAS Consortium Steering Committee (2009),
the authors recognize a new type of study called “integrated mega-analysis” that is different from
the conventional meta-analysis. Mega-analysis uses individual-level genotype and phenotype
data as opposed to summary data (such as Odds Ratios used in meta-analyses) and integrated
mega-analyses of all GWAS data might lead us toward the etiology of psychiatric diseases such
as MDD. According to the committee a conventional definition of MDD with the identification
of one or more compelling associations with a SNP, haplotype, or copy number variant could
become the “holy grail” of psychiatric genetics.
Genome-Wide Association Analysis of Age at Onset of Major Depressive Disorder
The SNP rs734253 in gene GPR143 was the best SNP with the strongest p-value at p = 2.54
x 10-12 along with three more genome-wide significant SNPs - rs6641545 in the gene ASS1P4,
rs5983118 in the gene MXRA5, rs6654462 flanked by the genes MAGEC1 and MAGEC2. In
addition, the gene PPARGC1B contained four SNPs (rs32589, p = 4.72x10-6; rs10515638, p =
9.77x10-6; rs26125, p = 1.04x10-5; rs17110375, p = 1.42x10-5) of high significance (p < 10-4)
along with the gene GRIK4 which contained one SNP rs3016415 also at high significance (p =
3.5x10-5).
While the top four SNPs have been found to be of GWAS significance, the associated genes
are novel in that none of them have been implicated in any specific disease association earlier.
Some passing observational references have been made in the gene databases, such as, the
MAGEC1/2 genes are seen in human melanoma and the GPR143 has been implicated in Ocular
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albinism. But, no direct association with MDD or any other mental disease has been made for
these novel genes.
A quick search in the gene databases revealed that the gene PPARGC1B has been associated
with obesity, metabolism, and body energy regulation (e.g., performance of athletes) and the
gene GRIK4 which has been implicated in neuronal signaling (Joslyn, Ravindranathan, Brush,
Schuckt, & White, 2010) and in an individual’s performance on standardized tests (Cirulli et al.,
2010). The gene GRIK4 has been implicated for strong remission of depression in depressive
patients undergoing anti-depressant therapy (Horstman et al., 2009). Functionally, GRIK4 gene
encodes a protein that belongs to the glutamate-gated ion channel family. Glutamate functions as
major excitatory neurotransmitter in the central nervous system through activation of ligandgated ion channels and G-protein coupled membrane receptors.
Many genetic linkage studies have been undertaken in the context of recurrent and early
onset MDD and the early age at onset has been considered as below the age of 31. Separate
adolescent studies have also been done and thus the current literature seems to have dealt with
age at onset under two categories – adolescent MDD and adult MDD.
Many associations have been made in the literature between early or late age at onset of
MDD and risky behaviors like alcohol abuse and cigarette smoking (e.g. Sund, Larsson, &
Wichstrom, 2011) and a study of brain anatomy (volume of amygdala) of older patients with
late-life depression (Burke et al., 2011). However, other than a study by Shi et al (2011) the
current literature does not show specific GWAS of AAO in MDD. The Shi study excludes
lifetime MDD and also focuses on people who were diagnosed with MDD before the age of 31
years.
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Thus, the current study reported in this dissertation seems to be first of its kind (populationbased study of age at onset of both adolescent and adult MDD) with a large 18-65 years MDD
cohorts which has found four novel genes (GPR143, ASS1P4, MXRA5 and two SNPs between
MAGEC1 and MAGEC2) with GWAS significance. It is hoped that future studies will be able to
replicate these GWAS significant MDD implicating genes in other populations in order that
AAO as a quantitative trait of MDD can become a basis for further elucidation of MDD and its
genetic variants.
The above finding of novel genetic variants for MDD using age at onset as a quantitative trait
means that our Hypothesis 3 (stated earlier in Chapter 1) is true. Again, we hasten to caution that
replication in other populations and specific functional associations need to be ascertained before
implicating these novel genes for MDD.

Strengths of the Study
The main strength of this study is that it is the first GWA study of the MDD related
quantitative traits of neuroticism scores and age at onset of MDD. Next, we have looked at the
gene x gender interactions of neuroticism associated with MDD cases and have unearthed some
novel genes and associated SNPs by the analysis of age at onset as a quantitative trait. These new
genes and their associated genomic regions can further be examined for functional significance
and other tag SNPs that may have been reported by other researchers for various mental
disorders and other complex diseases.
The gender differences we have found in the differing significant SNPs (p < 10-4) for
Neuroticism in men and women with MDD and the clear interactions between gene and gender
for the mean NEO scores (see Figure 5 in Appendix C) show the strength of using quantitative
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traits in GWAS. Elucidating the genetic basis of MDD by exploring other quantitative
phenotypes of MDD might lead to a narrowing of the set of genes that might be implicated for
MDD.
Discovery of novel genetic variants of MDD by the use of another quantitative trait (namely,
age at onset of MDD) points to possible first steps in understanding the etiology of MDD in
adolescents and young adults. Knowing the fact that young adults in the age group of 18-29
(Kessler et al., 2003) have one of the highest ORs (3.0) for MDD, understanding the genes
implicated by the age at onset of MDD further is an important public health undertaking in order
to craft early interventional strategies for that group of young adults. Furthermore, finding
common and significant (p < 0.05) genetic variants in two different populations (as we did for
neuroticism in the NESDA and ASPD in the Australian sample) might lead us to common
biological functional underpinnings that might one day help us in identifying newer
interventional strategies based on the specific functional proteins and signaling pathways.
While we are still years away from elucidating the etiology of MDD, adding new and
significant biomarkers (SNPs and genetic regions) to the existing databases may pave the way
for detecting and/or understanding of how genes can affect the development of MDD in
vulnerable populations.
As we have seen from our limited results of MDD vulnerability, both gender and family risks
must be studied further to look for possible public health intervention strategies to prevent early
onsets of MDD, progression from temporal to lifelong suffrage of MDD, and suicidal deaths
from MDD. Genetic and genome-wide association analyses are only the first step in terms of
using the power of newer genetic and bioinformatics technologies in order to enhance the
epidemiological methods available for combating MDD in our society.
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Limitations of the Study
A number of limitations must be recognized in this study. This is a preliminary study looking
at neuroticism as an endophenotype for MDD and as such needs to be replicated in several other
samples. Other than showing some associations at suggestive level (p < 5x10-4), not all
implicated SNPs reach the GWA significance level (p < 5x10-7). Our findings must be
interpreted with caution because of limitations of sample size and power.
While the initial phenotypic analyses using logistic regression methods confirmed the major
risk factors for MDD (female gender, marital status, etc.) further work needs to be done by
categorization of certain risk factors as age (in terms of specific age groups), marital status (in
terms of specific statuses as being single, widowed, same sex partner, etc.), and alcohol use (in
terms of teetotaler, casual drinker, moderate consumer, heavy drinker, and abuser). The alcohol
and/or tobacco use as a risk factor for any medical condition are in general viewed as being
contentious and both risk factors are highly complex to analyze. Our study does not adequately
address these two risk factors for MDD.
Genome-Wide studies have been criticized for not being able to find main effects of genes on
complex diseases such as MDD. Thus, this study must be expanded to include investigations of
specific vulnerable genetic regions (esp. within families) by using the latest New Generation
Sequencing (NGS) technologies, albeit with added expense to procure new equipment and
design new strategies to limit research for functional understanding of the known genes.
Conclusions and Further Recommendations
Our results showed female gender, family history of MDD, and smoking as major risk factors
for MDD, findings that are consistent with past studies. We found several significant SNPs (at p
< 10-4) for the association of neuroticism in MDD and significant gene x gender interactions
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implicating several new genes – TMPRSS9, GRIN2B, SGCA, HMCN1 and SNTG1. More
interestingly, we found four novel genes at genome-wide significance (p < 5x10-7) for age at
onset association with MDD. These novel genes are – GPR143 (p = 2.54x10-12), ASS1P4 (p =
9.75x10-10), MXRA5 (p = 5.67x10-8), and the genomic region between MAGEC1 and MAGEC2
(p = 3.99x10-7).
Much work remains to be done in the elucidation of genetic variations and the etiology of
MDD as a complex and chronic disease that affects millions of people around the world and
poses as a major global burden of disease. The results of our study contribute to expanding the
genetic basis of MDD. Replication studies in other population in order to elucidate the genetic
variants of MDD are needed.
A few recommendations for further study are in order –


Conduct replication studies of other non-European populations that are vulnerable to
MDD using neuroticism and age at onset as quantitative traits.



Discover other mental disorders that have same or similar genomic regions as what
we have found and study the interrelations and gene functionality that might explain
further biological mechanisms that make it possible for MDD to be inheritable in and
across families at rates of 40%-70%.



Use Haploview and other modern genetic software tools to find the tag SNPs from the
significant SNPs found in our study.



Procure funding for exploring the pertinent genomic regions significant for
neuroticism and age at onset using Next Generation Sequencing of human
chromosomes 1, 8, 12, 17, 19, and 23 (or X chromosome).
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APPENDICES
APPENDIX A
A1. Lifetime prevalence of Major Depressive Disorder and Age at Onset distributions
The literature indicates that until 2005 little was known about the lifetime prevalence or age
at onset of a number of DSM-IV disorders including MDD. Kessler et al. (2005) conducted a
study of 9282 English-speaking, nationally representative Americans aged 18 and older (from
the NCS-R sample) in order to estimate the distribution of lifetime prevalence and age at onset of
DSM-IV disorders. Their findings reported that about half of Americans will meet a DSM-IV
disorder criterion sometime in their life, with the first onset usually in childhood or adolescence.
Thus any intervention to prevent or treating early the symptoms of MDD must be focused on the
youth according to Kessler et al. (2005).
The results from Kessler et al. (2005) epidemiologic study indicate that the lifetime
prevalence estimates are as follows –

Table A1-1
Lifetime Prevalence Estimates
Age Group

Prevalence % (SE)

Total sample (18 – 60+)

16.6 (0.5)

Age 18 - 29

15.4 (0.7)

Age 30 - 44

19.8 (0.9)

Age 45 - 59

18.8 (1.1)

Age over 60

10.6 (0.8)

Ages at selected percentiles on the standardized age at onset distributions of MDD with
projected lifetime risk at age 75 are as follows –
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Table A1-2
Projected Lifetime Risk at Age 75
Projected Lifetime Risk
at age 75; 23.2% (0.6 SE)

Actual Age

Percentile 5

12

Percentile 10

14

Percentile 25

19

Percentile 50

32

Percentile 75

44

Percentile 90

56

Percentile 95

64

Percentile 99

73

The authors of the above study, however, point to four biases that should be noted 1.

People with a history of mental illness are less likely to participate in the study.

2.

Well-known bias of underreporting embarrassing behaviors.

3.

Estimation of lifetime risk was based on the assumption of constant conditional
risk of first onset in a given year of life among people of different ages at
interview.

4.

Recall bias of age at onset.

Given the enormous public health consequences of MDD, the above observations should lead
us to thinking about interventions early in childhood and adolescent years and prevention of
MDD and its comorbidities (Kessler et al., 2005).

115

A2. An Overview of WMH-CIDI
The World mental Health (WMH) Composite International Diagnostic Interview (CIDI) is a
collection of a screening module and has 40 sections with 22 sections that focus on diagnoses,
four sections on functioning, 2 sections on treatment, 4 sections on risk factors, 7 sections on
socio-demographic correlates, and 2 sections on methodological factors. A computer-based
version of the interview is available with direct data entry software using a keyboard. Diagnoses
based on ICD-10 and DSM-IV criteria are generated from the WMH-CIDI software. In addition,
CDROM-based training materials are available to teach the interviewers how to administer the
interview and teach the supervisors how to monitor the quality of data collected. A brief
description of the details (Kessler & Ustun, 2000) is presented below.
The diagnostic survey methodological issues consists of question and task comprehensions,
motivation, ability to answer diagnostic questions accurately, section to review one’s lifetime,
details of Part I and Part II diagnostics, and the expanded section to include such lifetime factors
as the socio-economic status (SES), family, and childhood experiences. The aim of the interview
is to obtain valid information about the prevalence, correlates, and unmet needs for treatment of
mental disorders in the general population as well as to determine the treatment adequacy and the
societal burden of mental disorders.
Question comprehension
Answering structured interview questions that are ambiguous is easily misconstrued by more
than 70% of the respondents as was shown by Belson (1981) and others (Oksenberg et al., 1991).
The problem in surveys is that the flow of questions is predetermined by the researcher and the
normal rules of conversation (e.g., give-and-take) do not apply and this is compounded when the
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topic of discussion is the emotional experiences of the respondent. Four discriminating features
among the high and low levels of misunderstandings are complexity, vagueness, multiple
interpretations of an odd experience, and contextual. The solution arrived to avoid the problems
in question understanding was to breakdown the complex questions into simpler subquestions.
Task comprehension
Second type of misunderstood response in CIDI came from people who did not understand
what they were being tasked to do when a response needed a considerable thought. Cannell et al.
(1981) has shown that this problem could be solved by instructing respondents to answer the
question completely and accurately. The stem question preceding questions that need clear
comprehension of the task at hand must be timed properly and also placed appropriately within
the survey along with a preface – “The next question may be difficult, so please take your time
before answering”.
Motivation
Getting valid responses needs motivation on the part of the respondent and thus motivational
instructions and contingent reinforcement during the interview (e.g., “You answered that very
quickly. Was there anything else, even something unimportant that you want to add?”) are
needed to enhance the validity of the responses. CIDI uses this type of contingent reinforcement
a part of their training materials developed for the WMH surveys. Another motivational aspect of
getting the respondent demur explicitly or tacitly work hard to give an honest answer is a part of
the common understanding between the interviewer and the respondent (e.g., Clark et al., 1992;
Loftus & Palmer, 1974).
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Ability to answer accurately
Episodic and semantic memories play a role in influencing the respondent’s accuracy in
answering questions. For example, the respondent may have a semantic memory of what panic
attacks are like, but after having many such attacks in one’s lifetime, one may not be able to
recall one attack accurately. Research has shown that people are more likely to recall episodic
memories more accurately than the semantic memories (say, from panic attacks) that are
frequent, typical, and regular. Thus, asking questions without knowing the limits of one’s
memory should be based on episodic memory for accuracy, whereas, clarification must precede
any questions about semantic memories. Thus, the designers of WMH-CIDI used pilots where
respondents were debriefed with an explicit eye towards pinpointing questions that were difficult
to answer.
Lifetime review section
One of the most important aspects of the CIDI is the life review cycle that is administered at
the beginning of the interview. This will both motivate and facilitate active memory search in
answering the diagnostic stem questions. This modification to the earlier CIDI led to a
significant increase in the proportion of respondents who endorsed the diagnostic stem questions
(Kessler et al., 1998). While some upward biasing questions were raised from some early
international surveys (e.g., as much as 50% increase in lifetime criteria for ICD or DSM mental
disorders), clinical calibration proved otherwise leading to add a clinical significance criterion to
many disorders in DSM-IV. However, some critics have argued for including some subthreshold
cases (e.g., Merikangas et al., 2003) in the definitions for mental disorders. Research-wise this
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might be important because full exploration of the continua rather than the currently established
threshold guidelines yields greater power in studies of genetic and environmental risk factors
(Benjamin et al., 1998). Further discussion on subthreshold disorders, symptom persistence and
severity, internal and external impairments, and the ranking of physical and mental disorders are
available in Kessler & Ustun, 2000.
Part I and Part II diagnoses
The WMH-CIDI is an elaborate instrument that takes up as many as 2 full hours to complete
the interview. In practice this would entail complications in order that the interview is done in
two parts – Part I and Part II. Part I includes all core diagnostic assessments and those who report
having no lifetime history of disorder are terminated at this midpoint of the interview. Part II is
completed by those diagnosed as being with lifetime disorder issues. Further elaboration of
subsampling of noncases to be included in Part II and other case-control and statistical power
issues are more fully discussed in Kessler and Ustun, 2000.
Other factors
The main reason behind developing WMH-CIDI was to expand a previous version of the
instrument and include assessments of risk factors, consequences, and treatment. Accordingly,
socio-demographics, treatment and pharmacoepidemiology, nonspecific psychological distress,
family burden, and childhood experiences are all included in specific subsections of the
interview. Socio-demographics include such predictors (or, risk factors) as age, gender, race,
educational attainment, marital status, and employment status. The idea here is to include the
dynamic information about achieved statuses in the interview schedule. Treatment and
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pharmacoepidemiology sections assess both internally and externally the patterns and predictors
of delays in initial treatment after first onset of disorder, lifetime hospitalization, and the type of
professionals the respondents have sought and seen. Nonspecific psychological distress
information gives the frequency and a scaled score from a screen for serious mental illness (SMI)
30 days before the interview and in the worst month of the past year. This information would be
very useful as an inexpensive mental health needs surveillance tool for public health
professionals. While the assessment of the respondent gives rise to excellent understanding of
how mental disorders affect the people with the disorders, it ignores the patient’s family. Thus,
the enormous family burden needs to be measured and a special section has been introduced to
assess the same in WMH-CIDI. After inquiring about a network of first degree relatives, the
respondent is asked about 12 serious health problems (cancer, heart problems, memory problem,
mental disorders like schizophrenia, manic depression, etc.) of those first order relatives. The
data collected here also helps in laying the ground work for any family-based genetic studies at a
later date. Finally, such childhood experiences as having a single parent or nonbiological parents,
trauma caused by authoritarian, overprotective or neglectful parents, any sexual abuse, etc. are
collected by a special section at the end of the CIDI interview. Separate assessments of parental
depression, panic disorder, general anxiety disorder, antisocial behaviors, and substance-abuse
disorders are made here.
The results from the WMH-CIDI interview are summarized in terms of quantitative scores
that are stored in a database and a final qualitative diagnosis of MDD is reached by a computer
program.
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APPENDIX B
Brief Summary of the Genomics and Genome-Wide Association Analyses Literature
Considering that the human genome was fully sequenced (i.e., over 90% of the functional
genome) in 2004 (International Human Genome Sequencing Consortium, 2004), and the first
GWAS of seven common diseases was published in 2007 (Wellcome Trust Case Control
Consortium, 2007), the literature of GWAS of MDD is rather limited. However, the
pathophysiology of MDD at genetic and molecular levels has been studied extensively in the past
3 to 5 years and many genes (and/or gene regions) have been implicated to be strongly associated
with MDD and its related phenotypes.
In addition to the complete sequencing of the functional human genome, the International
HapMap project, which was a collaborative project started in 2002 and completed in 2009, has
given us the ability to search the entire human genome for genetic variants. The HapMap project
was a collaborative effort between researchers in Canada, China, Japan, Nigeria, UK, and the US
and used samples from four groups as follows:


30 adults-and-both-parents trios (90 people) from Ibadan, Nigeria (YRI)



30 trios (90 people) US residents of northern and western European ancestry (CEU)



44 unrelated individuals from Tokyo, Japan (JPT), and



45 unrelated Han Chinese individuals from Beijing, China (CHB)

The genotyping of these diverse human populations has resulted in a SNP database
(dbSNP) of the complete human genome that has provided over 27 million SNPs for use in
genetic research and Genome-Wide studies.
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A brief summary of definitions, post-genomic era accomplishments, consensus, challenges
and uncertainties, positives and perils, and phenomics – the systematic study of phenotypes on a
genome-wide scale are discussed briefly below.
Definitions
In recent years (since 1980s), many new areas of genetics research have emerged, and thanks
to the completion of sequencing the known functional human genome in 2004 there has been an
even newer emergence of other ‘omics era. Some of the more important areas of research and the
terminology attributable to this new research are –


Public Health Genomics – Centers for Disease Control and Prevention (CDC) defines
Public Health genomics as an emerging field of study that assesses the impact of
genes and their interaction with behavior, diet and the environment on the
population’s health (Centers for Disease Control and Prevention, n.d.).



Genetic and Molecular Epidemiology – Morton defines this as “a science which deals
with the etiology, distribution, and control of disease in groups of relatives and with
inherited causes of disease in populations” (Morton, 1982). It is closely allied to both
molecular epidemiology and statistical genetics, but these overlapping fields each
have distinct emphases, societies, and journals.



Gene x Gene and Gene x Environment interactions – When two or more genes
interact to produce a single phenotype, gene x gene interaction is said to have taken
place. Genes may also interact with an environmental factor such as gender and
alcohol or tobacco usage to produce phenotypes that might be different than that
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would have resulted from the influence of the gene alone or with other genes (gene x
gene interaction). In mental disorders many normal physiological conditions such as
blood pressure and cognitive abilities such as intelligence probably result from the
combined action of multiple genes, each producing a small effect together with a
variety of environmental factors (Tsuang et al., 2004).


Genotype-phenotype databases – The genetic information is described in terms of the
sequence of nucleotides (A, C, T, G) comprising the DNA and the most common
form of genetic variation is in terms of a single nucleotide polymorphism (SNP). In
concert with the rapid availability of several genotyping technologies, the systematic
interrogation of the whole genome has become possible (Chanock et al., 2007). A
compilation of these varying genetic sequences of a specimen from an organism
(including the human) in an orderly way into a database represents a genotype
database. The establishment of an association between a genotype and a phenotype
constitutes a map, which when compiled into a database of associations would
constitute a phenotype database. Some of the well-known examples of genotype and
phenotype databases are – dbGaP (Database of Genotypes and Phenotypes), a
publicly available database for well-known diseases from NIH, GWAS Central,
containing the most comprehensive collection of summary level p-value GWAS data.
Also, dbSNP, the Single Nucleotide Polymorphism Database is a free public archive
for genetic variation within and across different species developed and hosted by the
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National Center for Biotechnology Information (NCBI) in collaboration with the
National Human Genome Research Institute (NHGRI).


Proteomics – A new branch of genomic sciences involving the large-scale study of
proteins, particularly their structures and functions (Anderson & Anderson, 1998).



Systems Biology and Metabolic Modeling - Kell (2006) opines that – “systems
biology involves an iterative interplay between more or less high-throughput and
high-content ‘wet’ experiments, technology development, theory and computational
modeling, and that it is the involvement of computational modeling, in particular, in
the process that sets systems biology apart from the more traditional and more
reductionist molecular biology”. Simply put, metabolic modeling consists of studying
metabolism at a molecular level using sophisticated computer-based algorithms to
determine the changes in the concentrations of enzymes (and the transcripts that
encode them) that have substantial effects on the concentrations of metabolic
intermediates.



Bioinformatics and Biobanks - In simple terms, Bioinformatics is the application of
computer science and statistics to the field of molecular biology. Since the 1980’s the
field of bioinformatics has grown to include the areas of genetics, genomics, and
DNA sequencing, while including creation and advancement of databases,
algorithms, computational and statistical techniques, and theory to solve problems
arising from the management and analyses of biological data (Hogeweg, 2011).
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Biobanks are the natural evolution of bioinformatic databases to store and document
access to biological samples and donor information (Macleod et al., 2009).


Epigenetics - Epigenetics is the study of heritable changes in the phenotype or gene
expression by something (usually environmental) other than changes in the DNA
sequence (Holliday, 1990).



Next Generation Sequencing - The genome sequencing efforts started back in 1991
and they entailed a laborious radiation-based method. According to Mun-Keat Looi
(2009), it used to take half a million British pounds (£’s) and 3 years to generate one
bacterial genome sequence. Now one can do 100 bacterial genomes with a single run
and newer technologies can do things that were inconceivable 2 or 3 years ago.
Without going into all the details (Jostins, 2009; Mun-Keat Looi, 2009), the newer
sequencing techniques use repeated cleaving (i.e., cutting up the DNA into
fragments), reading the base (by recognizing a specific colored dye terminator), and
moving to the next base in sequence without moving the piece of the segmented DNA
itself, but regenerating the whole segment in place. By having the DNA cut up into
several hundreds or thousands of contiguous pieces (called beads) in an array and
using automated techniques, machines are now able to read one gigabase of DNA
sequence in a couple of days at a cost of $0.02 per 1000 bases.

Post-genomic era accomplishment
Lesch (2004) summarizes the post-genomic era research into the genetics of depression as
follows:
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A predominant role in individual differences in depression-related traits (i.e.,
phenotypes) is confirmed to be played by the variation in genetic expression
among individuals.



Functional Neuroimaging has substantiated the gene-phenotype correlations.



Concept of gene networks controlling brain development has been recognized.



Gene-environment interactions in humans and animal models give rise to both
complexity of traits and establishment of specific phenotypes.

Hirschhorn and Daly (2005) acknowledge that genetic association studies offer a potentially
powerful approach for mapping causal genes with modest effects but also warn that only a small
number of genes can be studied at one time and that the contributions made by any single gene
are small. They also note the post-genomic era accomplishments in terms of deposition of
millions of SNPs into public data bases, rapid improvements in genotyping technology, and the
completion of the International HapMap Project (Gibbs et al., 2003).
Consensus, Challenges, and Uncertainties
The first wave of GWAS has improved our understanding of the genetic basis of many
complex traits such as diabetes, prostate and breast cancers, inflammatory bowel disease, and
many loci implicating these diseases have been found (McCarthy et al., 2008). In addition, the
National Cancer Institute (NCI) and National Human Genome Research Institute (NHGRI) have
published an updated list of GWAS as a catalog which is available on their web sites. Several
common variants influencing such continuous traits as lipids, height, and fat mass have also been
found (Diabetes Genetic Initiative, 2007; Frayling et al., 2007; Katheriresan et al., 2008; Sanna
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et al., 2008; Weedon et al., 2007). However, many challenges remain and compelling signals
highlighting previously unsuspected biology and known variants of implicated genes explain
only a fraction of the observed familial aggregation, thus limiting potential application for early
interventions. Much work needs to be done to obtain a complete inventory of variants at each
locus and determine the molecular mechanisms that are in play in order to determine the disease
risk. In addition, the joint effects of the gene and the environment need to be modeled and further
analyses are needed to determine the complete range of susceptibility variants to explain the
clustering in families and the multifactorial nature of the complex traits (McCarthy et al., 2008).
Positives, Protocols, and Perils
Neale and Purcell (2008) discuss GWAS in a more practical way of detecting phenotypic
associations of modest effect contrasting it from the previous linkage and candidate gene
approaches. Accordingly, they look at GWAS as being a study of hundreds of thousands of
single nucleotide polymorphisms (SNPs) in thousands of individuals looking to comprehensively
survey common genetic variation. More importantly, they outline some key analytic
considerations, study design, quality control, and data cleaning along with analysis and
replication of results in other samples.
Presently, two major initiatives, one in UK (Wellcome Trust Case Control Consortium –
WTCCC), and one in the US (Genetic Association Information Network – GAIN) are generating
GWAS data. The UK study is comprised of 2,000 case sample cohorts for each of the following
diseases – Tuberculosis, coronary heart disease, types 1 and 2 diabetes, Crohn’s disease,
rheumatoid arthritis, bipolar disorder, heart disease, and hypertension. The US study, on the
127

other hand, has generated approximately 600K markers for schizophrenia, bipolar disorder,
diabetic nephropathy, MDD, ADHD, and psoriasis. The data used in this dissertation also come
from the GAIN initiative in the US that can be found at
http://www.fnih.org/gain2/home_new.shtml.
Numerous resources (SNP chips, online resources, collaboration, and consortia) have been
instrumental in making GWAS popular in recent years. Commercially available SNP chips are
being offered by Illumina, Affymetrix, and Perlegen to provide genotyping services for
individuals and/or families. A number of internet-based resources provide information for
accessing and understanding the results of a GWAS – for example, the National Center for
Biotechnology Information (NCBI - http://www.ncbi.nlm.nih.gov) hosts dbGaP, the database of
Genotypes and Phenotypes. Other resources include linking information to professional and
peer-reviewed articles in PubMed (a searchable index of publications), GenBank (a genetic
sequence database), and Entrez (a search engine for nucleotide, protein, structure, taxonomy,
genome, expression, and chemical databases). In addition, a number of shared controls sets (for a
case-control study) are available from WTCCC and GAIN (pending an application process).
Neale and Purcell (2008) opine that a successful GWAS is through increasing sample size
that enables detection of variants of small effect. Pooling of case samples from across the UK
and US as well as drawing from the experience of analysts, geneticists, and clinicians on major
collections provide additional benefits. Some examples for the collaborative work include major
type 2 diabetes projects DGI, FUSION, and Novartis (Saxena et al., 2007), the International
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Multi-center ADHD Genetics (IMAGE) project (Bookes et al., 2006; Kuntsi et al., 2006), and
the NTR and NESDA biobank project (Boomsma et al., 2008).
Some of the perils that come with GWAS are selection and use of computer software
packages, study designs, and data quality control. Neale and Purcell (2008) describe a number of
issues arising out of software selection, design of a required study, and cleaning up of data.
Software packages like PLINK (Purcell et al., 2007), principal components analysis (Price et al.,
2006), Haploview (Barrett et al., 2005), and PBAT (Lange et al., 2004) are most commonly used
in GWAS as can be gleaned from the literature. Both case-control and association study designs
may be employed for a GWAS; however, case-control studies have been more popular and
careful selection of matched controls with a particular focus on the ancestry has been
recommended. Finally, the quality of the data used for analysis determines the accuracy with
which any results from a GWAS may be used to draw conclusions. Neale and Purcell (2007)
point to the following important issues –


Prior probability of a SNP showing true significance is rather low (5x10-7 is the
accepted GWAS significance as set up by the Wellcome Trust Consortium).



A good indicator of genotype probe performance is the call rate across the sample.
Call rates in excess of 85% are the expected norms used in GWAS.



Genotype reproducibility is another key measure assessed through international
sample duplication.



Potential batch effects arise since samples (DNA sources) are not done with the same
product at the same time.
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Minor allele frequency (MAF) thresholds are recommended (usually 1%) as many
studies do not have the power to detect significant association for very rare variation.



Testing for deviations from the Hardy-Weinberg equilibrium (HWE) or, more aptly,
Hardy-Weinberg proportions (Elston et al., 2010) may provide further information
about the validity of the genotypes from a SNP. A stringent threshold of 10-6 for
deviation from HWE is recommended to assure data quality.



Nonpaternity is a potential problem for family-based data when trio (i.e., patient and
his or her parents) and sibship (i.e., patient and his or her siblings) designs are
employed.



Population stratification is a confounding factor in case-control, population based
quantitative analysis. A correction for the inflated association may be applied using
the principal component analysis (Price et al., 2006).



The distribution of association of test statistics is a useful indicator for sources of
biases.

Further data cleaning considerations are available from the literature (Chanock et al., 2007;
Wellcome Trust Case Control Consortium, 2007). GWAS gives one the most extensive looks at
the genome for uncovering variations of disease predisposal, while not necessarily pointing the
new biochemical pathways leading to a complex and multifactorial disease. Given the difficulty
of mapping the genetic variants of neuropsychiatric disease such as MDD, any GWAS for MDD
and related disorders must be carried out with even greater care.
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Phenomics and Epigenomics
Phenomics is another emerging transdiscipline where phenotypes are systematically studied
on a genome-wide scale (Bilder et al., 2009). In the context of public health, phenomics research
might be useful to relate neural systems functioning to human behavior. One of the advantages of
studying phenotypes from a genome-wide perspective might be to generate phenotypes, not from
a conventional laboratory or a web-based assessment of behavior, but rather, by iteratively
refining phenotype assays based on prior genotype-phenotype associations. Vertically integrated
research teams, novel analytic strategies, and the informatics infrastructure may help phenomics
research in managing the sheer complexity involved in this sequel to genomics. Indeed, one of
the nine interdisciplinary research consortia supported by NIH Roadmap Initiative that started in
2007 is funding the phenomics research at UCLA to investigate two cognitive phenotypes
(Bilder et al., 2009).
In addition to phenomics, yet another area of new research is epigenomics, the science of
how genes might be modified by the environment while not changing the DNA sequence but still
affecting the gene expression by affecting the chromatin structure, packaging, methylation, and
other molecular modifications (Mehler, 2008). This is very important in understanding neurodegenerative diseases such as schizophrenia, bipolar disorder, and other brain developmental (or
neural regenerative) and/or evolutionary mechanisms. Further insights into these new research
areas are the subject of NIH roadmap for the future aiming to develop epigenome-wide analysis
as a staple of future biological characterization. Further details are available at the NIH roadmap
web site - http://nihroadmap.nih.gov/epigenomics/initiatives.asp. Some researchers are even
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calling these initiatives as the beginnings of the Human Phenome Project promising to realize the
vision of personalized medicine and rational neuropsychiatric diagnosis and treatment (Bilder et
al., 2009).
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APPENDIX C
Additional Descriptive Histograms and Plots of Selected MDD Predictors
Figure 4 and Figure 5 below show the univariate and Gene x Gender analyses of neuroticism
scores in our sample population.

Mean Neuroticism Total Scores for the genotypes of
the SNP – rs4806846.

Mean Neuroticism Total Scores for the genotypes of
the SNP – rs220549.

Figure 4. Distribution of Mean Neuroticism Scores

Gene x Gender Interaction of Neuroticism Total
Score for the SNP rs2430132 in HMCN1.

Gene x Gender Interaction of Neuroticism Total
Score for the SNP rs17674783 in SNTG1.

Figure 5. Gene x Gender Interaction in Neuroticism Scores
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APPENDIX D
Supplementary Tables from GWAS Studies of Neuroticism and Age at Onset

Table D-1
Genome-Wide Association Study Results of 34 Significant SNPs for Neuroticism in MDD*
CHR

Reference
SNP

Positiona

Gene Name

Gene

P-value

Location

Total

b

P-value
Male

c

P-value
Femaled

19

rs4806846

2361484

TMPRSS9

19p13.3

7.79E-06

0.001109

0.002405

12

rs220549

13828587

GRIN2B

12p12

1.05E-05

0.05337

0.0002437

17

rs1046329

45603905

SGCA

17q21

1.37E-05

0.1835

2.88E-05

2

rs6757820

147996163

ACVR2A

2q22.3

1.51E-05

0.003489

0.002758

6

rs4510687

96219582

6q16.1

2.49E-05

0.1229

0.0001593

3

rs985280

64083893

3p14.1

2.61E-05

0.07875

0.0009192

6

rs4342432

96195874

2.96E-05

0.1475

0.0001645

16

rs9807002

26184920

3.05E-05

0.1409

0.000289

14

rs9323020

21228477

14q11.2

3.29E-05

0.06499

0.0001355

17

rs8068962

9254866

STX8

17p12

3.32E-05

0.05502

0.001416

2

rs2344734

152400075

NEB

2q22

3.61E-05

0.1872

0.0005467

2

rs12620464

101396078

4.09E-05

0.04817

0.0006929

8

rs1608361

123732642

4.13E-05

0.08719

0.004728

2

rs10930046

162846229

4.68E-05

0.06334

0.001034

5

rs6894463

3266546

4.81E-05

0.001539

0.003872

17

rs2301685

32452234

4.94E-05

0.1001

0.002558

20

rs6065392

39870080

5.02E-05

0.06333

0.001298

11

rs10835855

32165526

5.15E-05

0.06333

0.001298

8

rs16915079

51685259

5.54E-05

0.03473

0.006221

(MANEA &
FUT9)
PSMD6

Near
EDDM3B

LOC1001315
52

ZHX3

8q24.13

20q12

Near

8q11.22

CYCSP22
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Table D-1 (Continued)
3

rs9834457

69604258

9

rs4837349

131024550

6

rs12198780

7501543

8

rs4871135

9

Near

3p14.1

6.10E-05

0.02482

0.000309

GOLGA2

9q34.11

6.42E-05

0.04986

0.0004275

RPS26P29

6p24.3

6.53E-05

0.05282

0.002184

121924955

7.33E-05

0.1549

0.0005861

rs4740720

3196279

7.63E-05

0.4673

0.0003664

9

rs4836644

131024527

8.00E-05

0.08905

0.0002971

5

rs298024

58977433

8.02E-05

0.05118

0.006706

17

rs17651665

32419258

8.43E-05

0.122

0.003107

1

rs6702388

163236984

8.49E-05

0.01127

0.0007732

23

rs6525630

144651865

LOC347422

Xq27.3

8.67E-05

0.03364

0.1668

13

rs1927860

52964897

THSD1

13q14.3

9.23E-05

0.2213

0.001113

18

rs8096705

39769843

9.30E-05

0.01499

0.02828

8

rs7013587

52954726

9.53E-05

0.0183

0.07478

8

rs7818832

52856493

9.70E-05

0.0235

0.07048

23

rs5930284

127728822

9.97E-05

0.007143

0.1926

LOC642487

GOLGA2

9q34.11

TLK2P1

17q12

ST18

8q11.23

*

CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism

a

Physical position is based on NCBI genome build 36.3.

b

Wald test asymptotic P-value for the association of neuroticism with MDD in the total sample.

c

Wald test asymptotic P-value for the association of neuroticism with MDD in the male sample.

d

Wald test asymptotic P-value for the association of neuroticism with MDD in the female sample.

Table D-2
Genome-Wide Association Study Results of 46 Significant SNPs for Gene x Gender Interaction of
Neuroticism*
CHR

Reference
SNP

Gene Name

1

rs2430132

HMCN1

8

rs17674783

SNTG1

Gene
Location

1q25.3q31.1
8q11-q12
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P-assoc
Totala

P-assoc
Maleb

P-assoc
Femalec

P_GxE

0.351

0.4283

0.6643

5.37E-06

0.8544

0.5047

0.999

6.92E-06

Table D-2 (Continued)
(MAP2K4 &

17

rs2612437

0.9471

0.526

0.5177

9.30E-06

12

rs11614157

0.0612

0.3835

0.2374

1.48E-05

4

rs244052

ENPEP

4q25

0.2467

0.9248

0.4139

1.53E-05

8

rs391798

SNTG1

8q11-q12

0.9659

0.483

0.8758

1.53E-05

4

rs13146994

ATP8A1

4p14-p12

0.3128

0.2118

0.4046

1.66E-05

20

rs6072394

0.2119

0.9787

0.3763

1.77E-05

3

rs9834626

RPL10AP6

3p14.2

0.6774

0.454

0.5157

1.78E-05

15

rs870335

SMAD3

15q22.33

0.9354

0.4891

0.411

2.28E-05

20

rs2326424

ADRA1D

20p13

0.04644

0.01311

0.2266

2.69E-05

14

rs17111534

LOC100288480

14q11.2

0.3991

0.9245

0.1688

2.78E-05

2

rs12692083

ISCA1P6

2q14.3

0.7659

0.2809

0.09403

2.83E-05

15

rs2415037

SMAD3

15q22.33

0.8592

0.5387

0.4015

3.00E-05

15

rs1532758

SMAD3

15q22.33

0.2269

0.973

0.07676

3.50E-05

8

rs1023979

0.2049

0.377

0.5902

3.65E-05

6

rs11970411

0.9345

0.8628

0.8696

3.66E-05

5

rs6595727

0.1771

0.02356

0.9237

3.68E-05

8

rs4412393

0.6117

0.06589

0.3106

3.75E-05

8

rs7832224

0.2561

0.8041

0.2023

4.21E-05

8

rs203929

0.4532

0.9125

0.7004

4.25E-05

8

rs12541061

0.1925

0.3405

0.5777

4.28E-05

8

rs12478804

0.05783

0.8438

0.3738

4.73E-05

2

rs12480036

0.2312

0.9315

0.4074

4.73E-05

8

rs203953

0.7064

0.7489

0.9391

4.79E-05

8

rs12543181

0.2308

0.2388

0.1487

5.11E-05

13

rs3905070

EFNB2

13q33

0.06431

0.2778

0.1601

5.44E-05

15

rs2946543

SYNGR2P1

15q13.2

0.3641

0.731

0.592

5.54E-05

1

rs11163755

0.6195

0.1876

0.3995

5.72E-05

8

rs2942805

0.786

0.7985

0.436

5.73E-05

18

rs10502673

0.05579

0.007379

0.1413

5.74E-05

MYOCD)
(PRP1R12A &
C12orf64)

TNFA1P3

EFR3A

B3GALT1

GALNT1

6q23

8q24.22

2q24.3

18q12.1
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Table D-2 (Continued)

*

15

rs11539519

0.7383

0.0272

0.1347

5.76E-05

5

rs6555484

ADCY2

5p15.3

0.1239

0.8236

0.01417

5.92E-05

3

rs2717294

ALG3

3q27.1

0.04133

0.4183

0.03417

6.02E-05

2

rs10194273

0.912

0.5944

0.8303

6.34E-05

8

rs4623452

0.8869

0.06411

0.1713

6.92E-05

17

rs7213039

TTLL6

17q21.32

0.2436

0.2449

0.7986

7.76E-05

4

rs3829753

DUX4C

4q35.2

0.6033

0.4975

0.7407

7.94E-05

8

rs1821122

0.169

0.2281

0.3058

8.02E-05

13

rs1325396

0.4129

0.5374

0.07007

8.28E-05

19

rs8112887

0.3088

0.7539

0.5337

8.31E-05

17

rs7209419

0.2892

0.2922

0.8286

8.37E-05

8

rs3104997

0.06863

0.06077

0.3434

8.54E-05

4

rs4532257

TN1P3

4q27

0.4698

0.4746

0.5356

8.68E-05

11

rs2457249

MIR708

11q14.1

0.3407

0.5289

0.1679

8.82E-05

3

rs1685442

0.8079

0.6051

0.2961

9.03E-05

TTLL6

17q21.32

CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism; MDD = Major Depressive

Disorder;
a, b, c

Wald test asymptotic P-value for the association of neuroticism with MDD in the total, male, and

female sample.

Table D-3
Genome-Wide Association Study Results of All Significant SNPs for ASPD in the Region of
Implicated Genes for Neuroticism*

CHR

Reference
SNP

Gene
Name

P-Neoneu
Totala

PNeoneu
Maleb

PNeoneu
Femalec

PMDDtotald

PMDDmalee

PMDDfemalef

OZASPD
pvalueg

19

rs4806846

TMPRSS9

7.79E-06

0.0011

0.0024

0.002

0.061

0.0185

N/A

19

rs4453628

TMPRSS9

N/A

N/A

N/A

N/A

N/A

N/A

0.0538

12

rs220549

GRIN2B

1.05E-05

0.0534

0.0002

0.055

0.971

0.0145

0.2521

12

rs1158541

GRIN2B

N/A

N/A

N/A

N/A

N/A

N/A

0.0577
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Table D-3 (Continued)

*

12

rs2192973

GRIN2B

N/A

N/A

N/A

N/A

N/A

N/A

0.0624

12

rs11055608

GRIN2B

0.9412

0.8302

0.5511

0.759

0.348

0.2884

0.0671

12

rs2216127

GRIN2B

0.0824

0.4308

0.0798

0.039

0.105

0.1781

0.0484

12

rs7974275

GRIN2B

0.865

0.9641

0.4977

0.461

0.757

0.2365

0.0194

14

rs9323020

EDDM3B

3.29E-05

0.0650

0.0001

0.008

0.234

0.0173

0.2237

14

rs10146821

OR10G2

0.0871

0.0701

0.7192

0.568

0.319

0.8758

0.0417

14

rs10483255

RANBP20
P

N/A

N/A

N/A

N/A

N/A

N/A

0.0269

14
14
14

rs2874103
rs970382
rs6571990

OR4E2
OR4E2
EDDM3A

0.1635
0.1826
N/A

0.8785
0.8555
N/A

0.0596
0.0638
N/A

0.223
0.225
N/A

0.329
0.305
N/A

0.3568
0.3741
N/A

0.0802
0.0901
0.0028

14

rs8013476

LOC1002
87557

N/A

N/A

N/A

N/A

N/A

N/A

0.0735

14
14

rs718433
rs2141971

RNASE1
RNASE1

0.7877
0.7169

0.6430
0.2254

0.5419
0.3192

0.841
0.397

0.732
0.778

0.5755
0.1487

0.0573
0.0045

17

rs8068962

STX8

3.32E-05

0.0550

0.0014

0.013

0.297

0.0156

N/A

17
17
17
17
17
17

rs7216692
rs6503203
rs9904459
rs7209802
rs4791838
rs3891720

STX8
STX8
STX8
STX8
STX8
STX8

N/A
N/A
N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A
N/A
N/A

N/A
N/A
N/A
N/A
N/A
N/A

0.0707
0.0453
0.0661
0.0295
0.0014
0.0224

2

rs2344734

NEB

3.61E-05

0.1872

0.0005

0.076

0.789

0.0279

N/A

8

rs16915079

CYCSP22

5.54E-05

0.0347

0.0062

0.066

0.306

0.1175

N/A

8

rs12375352

SNTG1

N/A

N/A

N/A

N/A

N/A

N/A

0.0781

CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism; MDD = Major Depressive

Disorder; ASPD = Anti-Social Personality Disorder.
a, b, c

Wald test asymptotic P-value for the association of neuroticism with MDD in the total, male, and

female sample.
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d, e, f
g

Wald test asymptotic P-value for the association with MDD in the total, male, and female sample.

Wald test asymptotic P-value for the association with ASPD in the OZALC sample.

Table D-4
Genome-Wide Association Study Results of All Significant SNPs for Age at Onset of MDD*
CHR

Reference
SNP

Gene Name

Gene
Location

P-MDDTotala

P-MDDMaleb

P-MDDFemalec

PNeoneud

23

rs734253

GPR143

Xp22.3

0.3747

N/A

0.8116

0.2357

23

rs6641545

ASS1P4

Xp22.33

0.7671

0.2733

0.2551

0.64

23

rs5983118

MXRA5

Xp22.33

0.398

N/A

0.1451

0.5025

23

rs17267483

HDX

Xq22.1

0.4358

0.01471

0.7501

0.1034

23

rs5971527

CXorf29

Xp21.2

0.8627

0.01623

0.09991

0.6139

23

rs6654462

N/A

N/A

0.3369

0.7451

0.1007

0.1432

23

rs5928558

ENSG000002
33571

N/A

0.04561

0.05098

0.1785

0.02767

23

rs6629704

PTCHD1

Xp22.11

0.603

0.3504

0.3814

0.02766

23

rs2490768

ZCCHC16

Xq23

0.03009

0.961

0.0249

0.9888

5

rs32589

PPARGC1B

5q32

0.7074

0.00509

0.01677

0.5262

23

rs5918490

SRPX

Xp21.1

0.00262

0.9286

0.00181

0.3342

23

rs5935125

ARHGAP6

Xp22.3

0.07788

0.00667

0.5328

0.01839

23

rs17343481

ENSG000002
38327

N/A

0.7615

0.3565

0.5175

0.1023

6

rs9294523

RPL5P19

6q15

0.5052

0.09523

0.04591

0.6942

23

rs12393485

N/A

N/A

0.439

0.01915

0.7968

0.4857

23

rs1468422

NDUFA1

Xq24

0.848

0.2351

0.5242

0.00049

5

rs10515638

PPARGC1B

5q32

0.8893

0.01328

0.1193

0.2302

5

rs26125

PPARGC1B

5q32

0.494

0.00681

0.00659

0.5332
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PAAOe

2.54E12
9.75E10
5.67E08
1.59E07
1.70E07
3.99E07
5.45E07
1.01E06
4.17E06
4.72E06
4.97E06
5.38E06
5.40E06
5.83E06
5.92E06
7.46E06
9.77E06
1.04E05

Table D-4 (Continued)
23

rs3861732

LOC1001286
01

Xq22.1

0.6901

0.1144

0.1834

0.9338

23

rs17219420

HDX

Xq21.1

0.6002

0.04163

0.6945

0.153

23

rs7883591

ZCCHC16

Xq23

0.2569

0.4755

0.1334

0.7061

23

rs5939057

ZCCHC16

Xq23

0.284

0.5247

0.1672

0.6689

5

rs17110375

PPARGC1B

5q32

0.62

0.07167

0.06859

0.07791

23

rs16980772

SCML2

Xp22

0.5505

0.04284

0.1247

0.6471

23

rs12846646

SAT1

Xp22.11

0.6008

0.2697

0.8674

0.1614

23

rs17245924

N/A

N/A

0.05341

0.02078

0.2747

0.00014
9

23

rs4562492

ENSG000002
38327

N/A

0.873

0.4318

0.9855

0.1903

23

rs11092550

NRK

Xq22.3

0.2293

0.9968

0.2005

0.8261

23

rs5909462

SCML2

Xp22

0.5655

0.01616

0.07903

0.4144

23

rs17301374

CCT4P2

Xq11.2

0.04026

0.8737

0.02666

0.7771

23

rs5909169

SCML2

Xp22

0.4384

0.07897

0.1091

0.735

23

rs1500725

IL1RAPL1

Xp22.1p21.3

0.8097

0.08988

0.3676

0.9017

23

rs4378112

SHC1P1

Xq11.1

0.3433

0.376

0.1647

0.7435

6

rs6570806

N/A

N/A

0.1601

0.08379

0.01287

0.8842

23

rs5970992

DDX53-

Xp22.11

0.5179

0.015

0.05175

0.7221

8

rs16938568

RDH10

8q21.11

0.6015

0.1612

0.9382

0.1362

12

rs11107320

LOC1001321
26

12q22

0.4294

0.2577

0.1283

0.1142

11

rs3016415

GRIK4

11q22.3

0.6102

0.01755

0.02508

0.8042

6

rs10947795

KCNK16

6p21.2p21.1

0.5245

0.01124

0.4695

0.2657

22

rs34074034

TTLL12

22q13.31

0.2529

0.01343

0.9774

0.4047
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1.06E05
1.25E05
1.32E05
1.34E05
1.42E05
1.65E05
1.69E05
1.73E05
2.27E05
2.37E05
2.53E05
2.68E05
2.78E05
3.10E05
3.23E05
3.23E05
3.27E05
3.36E05
3.41E05
3.50E05
3.71E05
3.85E05

Table D-4 (Continued)
23

rs35401330

BEND2

Xp22.13

0.3709

0.05472

0.06403

0.5005

5

rs11738269

CANX

5q35

0.8539

0.02931

0.1304

0.2636

6

rs1876155

SIM1

6q16.3q21

0.1498

0.06722

0.5046

0.9709

23

rs590779

MIR514-3

Xq27.3

0.7882

0.1753

0.8695

0.745

15

rs11630901

RPAP1

15q15.1

0.1481

0.00367

0.9168

0.5768

23

rs4279777

FRMPD4

Xp22.2

0.699

0.02068

0.4697

0.28

23

rs989059

EDA

Xq12q13.1

0.9774

0.1451

0.4568

0.1792

8

rs17211245

RDH10

8q21.11

0.3178

0.1653

0.6283

0.03658

11

rs4573685

GRIK4

11q22.3

0.8897

0.02289

0.09412

0.2065

23

rs4824251

MIR514-3

Xq27.3

0.4736

0.2621

0.1843

0.53

23

rs5907414

N/A

N/A

0.3992

0.3598

0.5648

0.05666

23

rs5927283

LOC392439

Xp21.1

0.08112

0.00244

0.6162

0.01826

10

rs11018112

N/A

N/A

0.8165

0.1413

0.311

0.4234

23

rs5987957

PLS3

Xq23

0.7859

0.8008

0.6477

0.317

23

rs7472960

ZCCHC16

Xq23

0.2121

0.03187

0.6583

0.4743

23

rs2266835

MAMLD1

Xq28

0.1681

0.1089

0.3787

0.2941

9

rs870186

0.6415

0.2125

0.2563

0.781

10

rs10824745

LOC283050

10q22.3

0.7293

0.04759

0.08453

0.7109

23

rs1076616

N/A

N/A

0.1157

0.2694

0.02248

0.3392

23

rs6635622

N/A

N/A

0.7288

0.1708

0.3339

0.06482

6

rs885463

LOC1001279
00

6q13

0.2756

0.02632

0.00426

0.3531

1

rs10888527

ZNF687

1q21.3

0.3616

0.01012

0.00621

0.2164

23

rs7883119

0.4177

0.01898

0.8102

0.6838
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3.89E05
3.95E05
3.97E05
3.99E05
4.07E05
4.37E05
4.45E05
4.70E05
5.02E05
5.27E05
5.40E05
5.64E05
5.64E05
5.68E05
5.77E05
5.79E05
5.85E05
6.25E05
6.30E05
6.61E05
6.73E05
7.28E05
7.53E05

Table D-4 (Continued)

*

11

rs4617622

LOC120364

11q23.1

0.8802

0.0819

0.3866

0.07239

23

rs12687753

RRM2P3

Xp11.4

0.3099

0.2069

0.08466

0.2026

23

rs5933909

ARHAGAP6

Xp22.3

0.05047

0.00654
7

0.3721

0.00349
8

20

rs397883

TBC1D20

20p11.21

0.3593

0.01551

0.5936

0.5771

23

rs1476012

ALAS2

Xp11.21

0.36

0.3883

0.1781

0.7389

23

rs222108

KLHL4

Xq21.3

0.5008

0.06171

0.8959

0.8097

16

rs8048267

ZFHX3

16q22.3

0.2389

0.03201

0.00284
5

0.5397

8

rs7837426

RDH10

8q21.11

0.4974

0.2174

0.8439

0.02799

2

rs13394360

N/A

N/A

0.4401

0.3643

0.1471

0.8868

5

rs17617710

CANX

5q35

0.9256

0.02371

0.2289

0.4248

23

rs5972323

DMD

Xq34

0.2193

0.05967

0.5964

0.01431

23

rs5984014

N/A

N/A

0.3235

0.1835

0.09834

0.8646

5

rs6895902

CANX

5q35

0.7987

0.0295

0.3488

0.338

7.56E05
7.88E05
7.89E05
8.07E05
8.22E05
8.37E05
8.37E05
8.49E05
8.90E05
9.31E05
9.32E05
9.81E05
9.91E05

CHR = Chromosome Number; SNP = Single Nucleotide Polymorphism; MDD = Major Depressive

Disorder;
a, b, c

Wald test asymptotic P-value for the association with MDD in the total, male, and female sample.

d

Wald test asymptotic P-value for the association of neuroticism with MDD in the total sample.

e

Wald test asymptotic P-value for the association of age at onset with MDD in the total sample.
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